|
Document And Entity Information (USD $)
|
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Feb. 17, 2012
|
Jun. 30, 2011
|
|
| Document and Entity Information [Abstract] | |||
| Entity Registrant Name | PDL BIOPHARMA, INC. | ||
| Document Type | 10-K | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity Common Stock, Shares Outstanding | 139,875,399 | ||
| Entity Public Float | $ 818,628,832 | ||
| Amendment Flag | false | ||
| Entity Central Index Key | 0000882104 | ||
| Entity Current Reporting Status | Yes | ||
| Entity Voluntary Filers | No | ||
| Entity Filer Category | Large Accelerated Filer | ||
| Entity Well-known Seasoned Issuer | Yes | ||
| Document Period End Date | Dec. 31, 2011 | ||
| Document Fiscal Year Focus | 2011 | ||
| Document Fiscal Period Focus | FY |
| X | ||||||||||
|
- Definition
If the value is true, then the document as an amendment to previously-filed/accepted document. No definition available.
|
| X | ||||||||||
|
- Definition
End date of current fiscal year in the format --MM-DD. No definition available.
|
| X | ||||||||||
|
- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY. No definition available.
|
| X | ||||||||||
|
- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. No definition available.
|
| X | ||||||||||
|
- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD. No definition available.
|
| X | ||||||||||
|
- Definition
The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, POS AM and Other. No definition available.
|
| X | ||||||||||
|
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument No definition available.
|
| X | ||||||||||
|
- Definition
Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. No definition available.
|
| X | ||||||||||
|
- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. No definition available.
|
| X | ||||||||||
|
- Definition
State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K. No definition available.
|
| X | ||||||||||
|
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. No definition available.
|
| X | ||||||||||
|
- Definition
Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Legal settlement expense to be paid within one year of the date of the statement of financial position. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The current portion of the aggregate tax effects as of the balance sheet date of all future tax deductions arising from temporary differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws; after deducting the allocated valuation allowance, if any, to reduce such amount to net realizable value. Deferred tax liabilities and assets are classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, are classified according to the expected reversal date of the temporary difference. An unrecognized tax benefit that is directly related to a position taken in a tax year that results in a net operating loss carryforward is presented as a reduction of the related deferred tax asset. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The noncurrent portion as of the balance sheet date of the aggregate carrying amount of all future tax deductions arising from temporary differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws; after the valuation allowance, if any, to reduce such amount to net realizable value. Deferred tax liabilities and assets are classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, is classified according to the expected reversal date of the temporary difference. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying value of the noncurrent portion of notes payable which were initially due after one year or beyond the normal operating cycle, if longer, and which are not otherwise defined in the taxonomy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying value of the current portion of notes payable which were initially due after one year or beyond the normal operating cycle, if longer, and which are not otherwise defined in the taxonomy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Condensed Consolidated Balance Sheets (Parentheticals) (USD $)
In Thousands, except Per Share data, unless otherwise specified |
Dec. 31, 2011
|
Dec. 31, 2010
|
|---|---|---|
| Preferred stock par value (in Dollars per share) | $ 0.01 | $ 0.01 |
| Preferred stock, shares authorized | 10,000 | 10,000 |
| Preferred stock, shares issued | 0 | 0 |
| Preferred stock, shares outstanding | 0 | 0 |
| Common stock par value (in Dollars per share) | $ 0.01 | $ 0.01 |
| Common stock, shares authorized | 250,000 | 250,000 |
| Common stock, shares issued | 139,680 | 139,640 |
| Common stock, shares outstanding | 139,680 | 139,640 |
| X | ||||||||||
|
- Definition
Face amount or stated value of common stock per share; generally not indicative of the fair market value per share. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Condensed Consolidated Statements Of Income (Unaudited) (USD $)
In Thousands, except Per Share data, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Revenues: | |||
| Royalties | $ 351,641 | $ 343,475 | $ 305,049 |
| License and other | 10,400 | 1,500 | 13,135 |
| Total revenues | 362,041 | 344,975 | 318,184 |
| Operating expenses: | |||
| General and administrative | 18,338 | 41,396 | 21,064 |
| Legal settlement | 92,500 | ||
| Total operating expenses | 18,338 | 133,896 | 21,064 |
| Operating income | 343,703 | 211,079 | 297,120 |
| Non-operating expense, net | |||
| Gain (loss) on retirement or conversion of convertible notes | (766) | (17,648) | 1,518 |
| Interest and other income, net | 593 | 468 | 1,004 |
| Interest expense | (36,102) | (43,529) | (19,357) |
| Total non-operating expense, net | (36,275) | (60,709) | (16,835) |
| Income before income taxes | 307,428 | 150,370 | 280,285 |
| Income tax expense | 108,039 | 58,496 | 90,625 |
| Net income | $ 199,389 | $ 91,874 | $ 189,660 |
| Net income per share | |||
| Basic (in Dollars per share) | $ 1.43 | $ 0.73 | $ 1.59 |
| Diluted (in Dollars per share) | $ 1.15 | $ 0.54 | $ 1.07 |
| Weighted average shares outstanding | |||
| Basic (in Shares) | 139,663 | 126,578 | 119,402 |
| Diluted (in Shares) | 177,441 | 178,801 | 184,400 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The net proceeds or assets obtained in excess of (less than) the net carrying amount of assets recorded, or assets distributed and liabilities assumed less than (in excess of) estimated litigation liability extinguished, in settlement of a litigation matter. Represents (for other than an insurance entity in its normal claims settlement process), the amount of income (expense) recognized in the period to settle pending or threatened litigation and insurance claims. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount represents the difference between the fair value of the payments made and the carrying amount of the debt at the time of its extinguishment. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cost of borrowed funds accounted for as interest that was charged against earnings during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This item represents investment income derived from investments in debt and equity securities consisting of interest income earned from investments in debt securities and on cash and cash equivalents, dividend income from investments in equity securities, and income or expense derived from the amortization of investment related discounts or premiums, respectively, net of related investment expenses. This item does not include realized or unrealized gains or losses on the sale or holding of investments in debt and equity securities required to be included in earnings for the period or for other than temporary losses related to investments in debt and equity securities which are included in realized losses in the period recognized, and does not include investment income from real or personal property, such as rental income. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
|
- Definition
Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The component of interest expense comprised of the periodic charge against earnings over the life of the financing arrangement to which such costs relate. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The net change during the reporting period in accrued legal settlement expense. No definition available.
|
| X | ||||||||||
|
- Definition
Purchase Of Call Options to reduce the potential dilution upon conversion of convertible notes. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The component of interest expense comprised of the periodic charge against earnings over the life of the financing arrangement to which such costs relate. Alternate captions include Noncash Interest Expense. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The net amount of deferred income taxes and income tax credits less the tax benefit from exercise of stock options. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Reductions in the entity's income taxes that arise when compensation cost (from non-qualified share-based compensation) recognized on the entity's tax return exceeds compensation cost from equity-based compensation recognized in financial statements. This element represents the cash inflow reported in the enterprise's financing activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Reductions in the entity's income taxes that arise when compensation cost (from non-qualified equity-based compensation) recognized on the entity's tax return exceeds compensation cost from equity-based compensation recognized in financial statements. This element reduces net cash provided by operating activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount represents the difference between the fair value of the payments made and the carrying amount of the debt at the time of its extinguishment. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in other noncurrent operating liabilities not separately disclosed in the statement of cash flows. No definition available.
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets,or income taxes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of cash paid for interest during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The net cash inflow or outflow from financing activity for the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The net cash inflow or outflow from investing activity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow from the entity's earnings to the shareholders. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash inflow associated with maturities (principal being due), prepayments and calls (requests of early payments) on securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Reductions in the entity's income taxes that arise when compensation cost (from non-qualified stock options) recognized on the entity's tax return exceeds compensation cost from non-qualified stock options recognized on the income statement. This element increases net cash provided by operating activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Purchase Of Call Options to reduce the potential dilution upon conversion of convertible notes net of taxes. No definition available.
|
| X | ||||||||||
|
- Definition
Reduction to additional paid in capital resulting from dividends legally declared or paid in excess of the balance in retained earnings. Such dividends may also be referred to as liquidating distributions or returns of capital. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation". Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This element represents the amount of recognized equity-based compensation related to restricted stock units during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). No definition available.
|
| X | ||||||||||
|
- Definition
Tax benefit associated with any equity-based compensation plan other than an employee stock ownership plan (ESOP). The tax benefit results from the deduction by the entity on its tax return for an award of stock that exceeds the cumulative compensation cost for common stock or preferred stock recognized for financial reporting. Includes any resulting tax benefit that exceeds the previously recognized deferred tax asset (excess tax benefits). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Increase in additional paid in capital due to warrants issued during the period. Includes also the proceeds of debt securities issued with detachable stock purchase warrants that are allocable to the warrants. These warrants qualify for equity classification and provide the holder with a right to purchase stock from the entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The change in unrealized holding gain (loss), net of tax, on available-for-sale securities included in a separate component of shareholders' equity during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Change in accumulated gains and losses from derivative instrument designated and qualifying as the effective portion of cash flow hedges, net of tax effect. The after tax effect change includes an entity's share of an equity investee's Increase or Decrease in deferred hedging gains or losses. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of shares issued during the period as a result of the conversion of convertible securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The gross value of stock issued during the period upon the conversion of convertible securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 1 - Organization and Business
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||
| Business Description and Basis of Presentation [Text Block] |
1.
Organization and Business
PDL BioPharma Inc. (we, us, our, PDL
and the Company) pioneered humanization of monoclonal
antibodies and, by doing so, enabled the discovery of a new
generation of targeted treatments for cancer and immunologic
diseases. Today, PDL is focused on intellectual property
asset management, investing in new royalty bearing assets and
maximizing the value of its patent portfolio and related
assets. We receive
royalties based on sales of humanized antibody products
marketed today and may also receive royalty payments on
additional humanized antibody products launched before final
patent expiry in December 2014. Under most of our licensing
agreements, we are entitled to receive a flat-rate or tiered
royalty based upon our licensees’ net sales of covered
antibodies. We have also entered into licensing
agreements under which we have licensed certain rights for
development stage products that have not yet reached
commercialization including products that are currently in
Phase 3 clinical trials.
In
the year ended December 31, 2011, we received royalties
on sales of the seven humanized antibody products listed
below, all of which are currently approved for use by the
U.S. Food and Drug Administration (FDA) and other regulatory
agencies outside the United States. In the years ended
December 31, 2011, 2010 and 2009, we received
approximately $351.6 million, $343.5 million and $305.0
million, respectively, of royalty revenues under license
agreements.
We
have also entered into licensing agreements under which we
have licensed certain rights under our patents for
development-stage products that have not yet reached
commercialization including products that are currently in
Phase 3 clinical trials.
Until
December 2008, our business included biotechnology operations
which were focused on the discovery and development of novel
antibodies which we spun off (the Spin-Off) to Facet Biotech
Corporation (Facet). In April 2010, Abbott Laboratories
(Abbott) acquired Facet and later renamed the company Abbott
Biotherapeutics Corp.
|
| X | ||||||||||
|
- Definition
The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). No definition available.
|
|
Note 2 - Summary of Significant Accounting Policies
|
12 Months Ended | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||
| Basis of Presentation and Significant Accounting Policies [Text Block] |
2.
Summary of Significant Accounting Policies
Basis
of Presentation
The accompanying
consolidated financial statements have been prepared in
accordance with U.S. generally accepted accounting principles
(GAAP) and under the rules and regulations of the Securities
and Exchange Commission (SEC).
Principles
of Consolidation
The
consolidated financial statements include the accounts of the
Company and its wholly-owned subsidiary, QHP Royalty Sub LLC
(QHP). All material intercompany balances and transactions
are eliminated in consolidation. We prepare our consolidated
financial statements in accordance with the SEC and GAAP and
include all adjustments of a normal recurring nature that are
necessary to fairly present our consolidated results of
operations, financial position and cash flows for all periods
presented.
Management
Estimates
The
preparation of financial statements in conformity with GAAP
requires the use of management’s estimates and
assumptions that affect the amounts reported in the financial
statements and accompanying notes. Actual results could
differ from those estimates.
Segment
Disclosures
We
are required to report operating segments and make related
disclosures about our products, services, geographic areas
and major customers. Our chief operating decision-maker
consists of our executive management. Our chief operating
decision-maker reviews our operating results and operating
plans and makes resource allocation decisions on a
company-wide or aggregate basis. As of December 31,
2011, we operated as one segment. Our operations and
facilities are located in Incline Village, Nevada.
Cash
Equivalents and Investments
We
consider all highly liquid investments with initial
maturities of three months or less at the date of purchase
to be cash equivalents. We place our cash, cash equivalents
and investments with high credit quality financial
institutions and in U.S. government securities,
U.S. government agency securities and investment grade
corporate debt securities and, by policy, limit the amount
of credit exposure in any one financial instrument.
Available-for-sale securities are reported at fair value,
with unrealized gains and losses recorded in accumulated
other comprehensive income (loss). See Note 5.
Fair
Value Measurements
The
fair value of our financial instruments are estimates of the
amounts that would be received if we were to sell an asset or
we paid to transfer a liability in an orderly transaction
between market participants at the measurement date or exit
price. The assets and liabilities are categorized and
disclosed in one the following three categories:
Level
1 – based on quoted market prices in active markets for
identical assets and liabilities;
Level
2 – based on quoted market prices for similar assets
and liabilities, using observable market based inputs or
unobservable market based inputs corroborated by market data,
and
Level
3 – based on unobservable inputs using
management’s best estimate and assumptions when inputs
are unavailable. As of December 31, 2011 and 2010, we had no
Level 3 assets or liabilities.
We
do not estimate the fair value of our royalty assets for
financial statement reporting purposes.
Foreign
Currency Hedging
We
hedge certain Eurodollar currency exposures related to our
licensees’ product sales with Eurodollar forward
contracts and Eurodollar option contracts (collectively,
Eurodollar contracts). In general, these contracts are
intended to offset the underlying Eurodollar market risk in
our royalty revenues. Our exposure to credit risk from
these contracts is a function of foreign currency exchange
rates and, therefore, varies over time. We transact with
major banks to limit the credit risk that our counterparty
may be unable to perform and monitor the exposure in the
context of current market conditions. We mitigate the risk
of loss by entering into a netting agreement with our
counterparty that provides for aggregate net settlement of
all of the Eurodollar contracts should our counterparty
default on the contracts prior to contract settlement.
Therefore, our overall risk of loss in the event of
counterparty default is limited to the net amount of any
unrecognized gains or losses on outstanding contracts at
the date of default. We do not enter into speculative
foreign currency transactions. We have designated the
Eurodollar contracts as cash flow hedges. At the inception
of the hedging relationship and on a quarterly basis, we
assess hedge effectiveness. The aggregate unrealized gain
or loss on the effective component of our Eurodollar
contracts, net of estimated taxes, is recorded in
stockholders’ deficit as accumulated other
comprehensive income (loss). Gains or losses on cash flow
hedges are recognized as royalty revenue in the same period
that the hedged transaction, royalty revenue, impacts
earnings.
Revenue
Recognition
Royalty
Revenues
Under
most of our patent license agreements, we receive royalty
payments based upon our licensees’ net sales of covered
products. Generally, under these agreements we receive
royalty reports from our licensees approximately one quarter
in arrears, that is, generally in the second month of the
quarter after the licensee has sold the royalty-bearing
product. We recognize royalty revenues when we can reliably
estimate such amounts and collectability is reasonably
assured. As such, we generally recognize royalty revenues in
the quarter reported to us by our licensees, that is, royalty
revenues are generally recognized one quarter following the
quarter in which sales by our licensees occurred. Under this
accounting policy, the royalty revenues we report are not
based upon our estimates and such royalty revenues are
typically reported in the same period in which we receive
payment from our licensees.
We
may also receive minimal annual maintenance fees from
licensees of our Queen et al. patents prior to patent expiry
as well as periodic milestone payments. We have no
performance obligations with respect to such fees.
Maintenance fees are recognized as they are due and when
payment is reasonably assured. Total annual milestone
payments in each of the last several years have been less
than 1% of total revenue.
Comprehensive
Income (Loss)
Comprehensive
income (loss) comprises net income adjusted for other
comprehensive income (loss), which includes the changes in
unrealized gains and losses on Eurodollar contracts and
changes in unrealized gains and losses on our investments
in available-for-sale securities, if any, which are
excluded from our net income. The components and
accumulated balances of comprehensive income (loss)
were:
Property
and Equipment
Property
and equipment are stated at cost less accumulated
depreciation and amortization. Depreciation and amortization
were computed using the straight-line method over the
following estimated useful lives:
Recent
Accounting Pronouncements
In
June 2011, the Financial Accounting Standards Board (FASB)
issued accounting standard update (ASU) 2011-05, eliminating
the option to present the components of other comprehensive
income as part of the statement of changes in
stockholders’ equity. The update requires presentation
for items of net income and other comprehensive income either
in one continuous statement or in two separate, but
consecutive, statements. Additionally, this ASU includes a
new requirement to show reclassification adjustments from
other comprehensive income to net income on the face of the
statement. Except for, the new requirement to show
reclassification adjustments from other comprehensive income
to income on the face of the income statement, this guidance
is required for our first quarter of 2012 with retrospective
application also required. We
do not expect this guidance to have a material impact on our
financial statements.
|
| X | ||||||||||
|
- Definition
The entire disclosure for the basis of presentation, or accounting, and significant accounting policies. No definition available.
|
|
Note 3 - Net Income per Share
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Earnings Per Share [Text Block] |
3.
Net Income per Share
We
compute net income per basic share using the weighted-average
number of shares of common stock outstanding during the
period less the weighted-average number of restricted stock
shares that are subject to repurchase.
We
compute net income per diluted share using the sum of the
weighted-average number of common and common equivalent
shares outstanding. Common equivalent shares used in the
computation of net income per diluted share include shares
that may be issued under our stock options and restricted
stock awards, our 2.00% Convertible Senior Notes due
February 15, 2012 (2012 Notes), our 2.875% Convertible
Senior Notes due February 15, 2015 (February 2015
Notes), and our 2.75% Convertible Subordinated Notes due
August 16, 2023 (2023 Notes), on a weighted average
basis for the period that the notes were outstanding,
including the effect of adding back interest expense and the
underlying shares using the if-converted method. Our 2023
Notes were fully retired as of September 14, 2010. Our 2012
Notes were fully retired as of June 30, 2011.
The
computation for net income per basic and diluted share
was:
We
excluded 0.2 million, 0.3 million, and 2.5 million
of outstanding stock options from our net income per diluted
share calculations for the years ended December 31,
2011, 2010 and 2009, respectively, because the option
exercise prices were greater than the average market prices
of our common stock during these periods; therefore, their
effect was anti-dilutive.
In
May 2011, we issued 3.75% Senior Convertible Notes due May
1, 2015 (May 2015 Notes). If converted, the principal
amount of our May 2015 Notes will be settled in cash and
the difference between the conversion value and the
principal amounts will be settled in shares of the
Company’s common stock. For the year ended December
31, 2011, we excluded a weighted average of 13.3 million
shares of potential dilution for our May 2015
Notes and a weighted average of 13.3 million shares of
potential dilution for our warrants because the conversion
price and exercise price exceeded the average market price
of our common stock and were therefore anti-dilutive. These
securities could be dilutive in future periods. In
addition, we excluded a weighted average of (13.3) million
shares for our purchased call options because they will
always be anti-dilutive, therefore, will have no
effect on diluted net income per share.
For
information related to the conversion rates on our
convertible debt, see Note 12.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for earnings per share. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 4 - Fair Value Measurements
|
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fair Value Disclosures [Text Block] |
4. Fair Value
Measurements
Assets
and liabilities recorded at fair value, by classification
category by level of input within the fair value hierarchy
defined in Note 2, Summary of Significant Accounting
Policies:
The
fair value of the foreign currency hedging contracts is
estimated based on pricing models using readily observable
inputs from actively quoted markets and are disclosed on a
gross basis.
Corporate
debt securities consist primarily of U.S. Corporate bonds.
The fair value of corporate debt securities is estimated
using recently executed transactions or market quoted
prices, where observable. Independent pricing sources are
also used for valuation. No corporate debt securities had
been moved from Level 1 inputs to Level 2 inputs at
December 31, 2011, as compared to December 31,
2010.
The
fair value of commercial paper is estimated based on
observable inputs of the comparable securities.
We
do not estimate the fair value of our royalty assets for
financial statement reporting purposes.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 5 - Cash Equivalents, Short-term and Long-term Investments
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash, Cash Equivalents, and Marketable Securities [Text Block] |
5.
Cash Equivalents and Investments
As
of December 31, 2011 and 2010, we had invested our
excess cash balances primarily in money market funds,
corporate debt securities, commercial paper, U.S. government
sponsored agency bonds and U.S. treasury securities. Our
securities are classified as available-for-sale and are
carried at estimated fair value, with unrealized gains and
losses reported in accumulated other comprehensive income
(loss) in stockholders’ deficit, net of estimated
taxes. See Note 4 for fair value measurement information. The
cost of securities sold is based on the specific
identification method. To date, we have not experienced
credit losses on investments in these instruments and we do
not require collateral for our investment activities.
A
summary of our available-for-sale securities at
December 31, 2011 and 2010, is presented below:
We
did not recognize any gains or losses on sales of
available-for-sale securities during 2011, 2010 and
2009.
A
summary of our portfolio of available-for-sale debt
securities by contractual maturity at December 31, 2011
and 2010, is presented below:
The
unrealized loss on investments included in other
comprehensive income (loss), net of estimated taxes, was
approximately $29,000 as of December 31, 2011, and $1,000 as
of December 31, 2010. No significant facts or
circumstances have arisen to indicate that there has been any
deterioration in the creditworthiness of the issuers of these
securities. Based on our review of these securities, we
believe we had no other-than-temporary impairments on these
securities as of December 31, 2011, because we do not
intend to sell these securities and it is more likely than
not that we will hold these securities until the recovery of
their amortized cost basis.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss). No definition available.
|
|
Note 6 - Foreign Currency Hedging
|
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Derivative Instruments and Hedging Activities Disclosure [Text Block] |
6.
Foreign Currency Hedging
Our
licensees operate in foreign countries, which exposes us to
market risk associated with foreign currency exchange rate
fluctuations between the U.S. dollar and other currencies,
primarily the Eurodollar. In order to manage the risk related
to changes in foreign currency exchange rates, we entered
into a series of Eurodollar contracts covering the quarters
in which our licensees’ sales occur through December
2012. Our Eurodollar contracts used to hedge royalty revenues
based on underlying Eurodollar sales are designated as cash
flow hedges.
The
following tables summarize the notional amounts, Eurodollar
exchange rates, fair values of our open Eurodollar contracts
designated as cash flow hedges and their location on the
Consolidated Balance Sheet:
Eurodollar
contracts are presented on a net basis on our Consolidated
Balance Sheets as we have entered into a netting arrangement
with the counterparty. As of December 31, 2011, the
unrealized net loss on the effective component of our
Eurodollar contracts included in other comprehensive income
(loss), net of estimated taxes, was $(1.9) million. As of
December 31, 2010, the unrealized net gain on the
effective component of our Eurodollar contracts included in
other comprehensive income (loss), net of estimated taxes,
was $3.2 million. There ineffective component of our foreign
currency exchange contracts for the year ended
December 31, 2011, was $18,874 and there was no
ineffectiveness for the year ended December 30, 2010.
For
the years ended December 31, 2011 and 2010, we
recognized $1.0 million and $5.2 million in royalty revenues
from foreign currency exchange contracts, respectively.
Approximately $1.2 million, net of tax, is expected to be
reclassified from other comprehensive income (loss) against
earnings in the next 12 months. We did not have foreign
currency exchange contracts prior to 2010.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for the entity's entire derivative instruments and hedging activities. Describes an entity's risk management strategies, derivatives in hedging activities and non-hedging derivative instruments, the assets, obligations, liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 7 - Prepaid and Other Current Assets
|
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Prepaid And Other Current Assets [Text Block] |
7.
Prepaid and Other Current Assets
For
further information about our Non-recourse Notes, see Note
12, Convertible Notes and Non-Recourse Notes.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for prepaid and other current assets. No definition available.
|
|
Note 8 - Property and Equipment
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Property, Plant and Equipment Disclosure [Text Block] |
8.
Property and Equipment
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 9 - Other Assets
|
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets Disclosure [Text Block] |
9.
Other Assets
For
further information about our convertible notes and our
Non-recourse Notes, see Note 12, Convertible Notes and
Non-Recourse Notes.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for other assets. No definition available.
|
|
Note 10 - Accrued Liabilities
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accounts Payable and Accrued Liabilities Disclosure [Text Block] |
10.
Accrued Liabilities
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 11 - Commitments and Contingencies
|
12 Months Ended | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||
| Commitments and Contingencies Disclosure [Text Block] |
11.
Commitments and Contingencies
Operating
Leases
Current
Facilities and Equipment
We
currently occupy a leased facility in Incline Village,
Nevada, with a lease term through May 2012. We also lease
certain office equipment under operating leases. Rental
expense under these arrangements totaled $0.2 million,
$0.1 million and $0.2 million for the years ended
December 31, 2011, 2010 and 2009.
As
of December 31, 2011, the future minimum operating lease
payments were:
Contingencies
As
permitted under Delaware law, under the terms of our bylaws,
we have agreed to indemnify our directors and officers and,
under the terms of indemnification agreements we have entered
into, we have agreed to indemnify our executive officers and
directors for certain events or occurrences, subject to
certain limits, while the officer or director is or was
serving as an officer or director of the Company. While the
maximum amount of potential future indemnification is
unlimited, we have a director and officer insurance policy
that limits our exposure and may enable us to recover a
portion of any future amounts paid. We believe the fair value
of these indemnification agreements and bylaw provisions is
minimal and, accordingly, we have not recorded the fair value
liability associated with these agreements as of
December 31, 2011 and 2010.
|
||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for commitments and contingencies. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 12 - Convertible and Non-Recourse Notes
|
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Long-term Debt [Text Block] |
12.
Convertible Notes and Non-recourse Notes
Convertible
and Non-recourse Notes activity for the year ended December
31, 2011, and fair value at December 31, 2011:
May
2015 Notes
On
May 16, 2011, we issued $155.3 million in aggregate principal
amount, at par, of our May 2015 Notes in an underwritten
public offering, for net proceeds of $149.7 million. Our May
2015 Notes are due May 1, 2015, and are convertible into
135.9607 shares of the Company’s common stock per
$1,000 of principal amount, or approximately $7.36 per share,
subject to further adjustment upon certain events including
dividend payments. We pay interest at 3.75% on our May 2015
Notes semiannually in arrears on May 1 and November 1 of each
year, beginning November 1, 2011. Proceeds from our May 2015
Notes, net of amounts used for purchased call option
transactions and provided by the warrant transactions
described below, were used to redeem our 2012 Notes. Upon the
occurrence of a fundamental change, as defined in the
indenture, holders have the option to require PDL to
repurchase their May 2015 Notes at a purchase price equal to
100% of the principal, plus accrued interest.
Our
May 2015 Notes are convertible under any of the following
circumstances:
If
a conversion occurs, to the extent that the conversion value
exceeds the principal amount, the principal amount is due in
cash and the difference between the conversion value and the
principal amount is due in shares of the Company’s
common stock. As of December 31, 2011, the if-converted
amount of our May 2015 Notes was less than the principal
amount.
In
accordance with the accounting guidance for convertible debt
instruments that may be settled in cash or other assets on
conversion, we were required to separately account for the
liability component of the instrument in a manner that
reflects the market interest rate for a similar
nonconvertible instrument at the date of issuance. As a
result, we separated the principal balance of our May 2015
Notes between the fair value of the debt component and the
fair value of the common stock conversion feature. Using an
assumed borrowing rate of 7.5%, which represents the
estimated market interest rate for a similar nonconvertible
instrument available to us on the date of issuance, we
recorded a total debt discount of $18.9 million, allocated
$12.3 million to additional paid-in capital and $6.6 million
to deferred tax liability. The discount is being amortized to
interest expense over the term of our May 2015 Notes and
increases interest expense during the term of our May 2015
Notes from the 3.75% cash coupon interest rate to an
effective interest rate of 7.5%. As of December 31, 2011, the
remaining discount amortization period is 3.3 years.
The
carrying value and unamortized discount of our May 2015 Notes
were:
Interest
expense for our May 2015 Notes on the Consolidated Statements
of Income was:
In
connection with the issuance of our May 2015 Notes, we
entered into purchased call option transactions with two
hedge counterparties entitling the Company to initially
purchase up to 19.6 million shares of the Company’s
common stock. In addition, we sold to the hedge
counterparties warrants exercisable, on a cashless basis, for
up to 27.5 million shares of the Company’s common
stock. The purchased call option transactions and warrant
sales effectively serve to reduce the potential dilution
associated with conversion of our May 2015 Notes. The strike
prices are approximately $7.36 and $8.65, subject to further
adjustment upon certain events including dividend payments,
for the purchased call options and warrants,
respectively.
If
the share price is above $7.36, upon conversion of our May
2015 Notes, the purchased call options will offset the
share dilution, because the Company will receive shares on
exercise of the purchased call options equal to the shares
that the Company must deliver to the note holders. If the
share price is above $8.65, upon exercise of the warrants,
the Company will deliver shares to the counterparties in an
amount equal to the excess of the share price over $8.65. For
example, a 10% increase in the share price above $8.65 would
result in the issuance of 1.9 million incremental shares upon
exercise of the warrants. As our share price continues to
increase, additional dilution would occur.
While the purchased call options are
expected to reduce the potential equity dilution upon
conversion of our May 2015 Notes, prior to conversion or
exercise, our May 2015 Notes and the warrants could have a
dilutive effect on the Company’s earnings per share to
the extent that the price of the Company’s common stock
during a given measurement period exceeds the respective
exercise prices of those instruments. As of
December 31, 2011, the market price condition for
convertibility of our May 2015 Notes was not met and there
were no related purchased call options or warrants
exercised.
The
purchased call options and warrants are considered indexed to
PDL stock, require net-share settlement, and met all criteria
for equity classification at inception and at December 31,
2011. The purchased call options cost, including legal fees,
of $20.8 million, less deferred taxes of $7.2 million, and
the $10.9 million received for the warrants were recorded as
adjustments to additional paid-in capital. Subsequent changes
in fair value will not be recognized as long as the purchased
call options and warrants continue to meet the criteria for
equity classification.
Purchased
Call Options
We
paid an aggregate amount of $20.8 million to two hedge
counterparties, plus legal fees, for the purchased call
options with terms substantially similar to the embedded
conversion options in our May 2015 Notes. The purchased call
options cover, subject to anti-dilution and certain other
customary adjustments substantially similar to those in our
May 2015 Notes, approximately 21.1 million shares of our
common stock at a strike price of approximately $7.36, which
corresponds to the conversion price of our May 2015 Notes. We
may exercise the purchased call options upon conversion of
our May 2015 Notes and require the hedge counterparty to
deliver shares to the Company in an amount equal to the
shares required to be delivered by the Company to the note
holder for the excess conversion value. The purchased call
options expire on May 1, 2015, or the last day any of our May
2015 Notes remain outstanding.
Warrants
We
received an aggregate amount of $10.9 million from the two
hedge counterparties for the sale of rights to receive up to
27.5 million shares of common stock underlying our May 2015
Notes, at a current strike price of approximately $8.65 per
share, subject to additional anti-dilution and certain other
customary adjustments. The warrant counterparties may
exercise the warrants on their specified expiration dates
that occur over a period of time ending on January 20, 2016.
If the volume weighted average share price of our common
stock, as defined in the warrants (VWAP), exceeds the strike
price of the warrants, we will deliver to the warrant
counterparties shares equal to the spread between the VWAP on
the date of exercise or expiration and the strike price. If
the VWAP is less than the strike price, neither party is
obligated to deliver anything to the other.
February
2015 Notes
On
November 1, 2010, we completed an exchange of $92.0
million in aggregate principal of our 2012 Notes in separate,
privately negotiated transactions with the note holders. In
the exchange transactions, the note holders received
$92.0 million in aggregate principal of our February
2015 Notes, and we recorded a net gain of $1.1 million. As
part of the transaction, we placed an additional $88.0
million in aggregate principal of our February 2015 Notes.
Our February 2015 Notes are due February 15, 2015, and
are convertible at any time, at the holders’ option,
into our common stock at a conversion price of
155.396 shares of common stock per $1,000 principal
amount, or $6.44 per share, subject to further adjustment in
certain events including dividend payments. We pay interest
on our February 2015 Notes semiannually in arrears on
February 15 and August 15 of each year. Our
February 2015 Notes are senior unsecured debt and are
redeemable by us in whole or in part on or after
August 15, 2014, at 100% of principal amount. Our
February 2015 Notes are not puttable by the note holders
other than in the context of a fundamental change resulting
in the reclassification, conversion, exchange or cancellation
of our common stock. Such repurchase event or fundamental
change is generally defined to include a merger involving
PDL, an acquisition of a majority of PDL’s outstanding
common stock and a change of a majority of PDL’s board
of directors without the approval of the board of directors.
Our February 2015 Notes issuance was not registered under the
Securities Act of 1933, as amended, in reliance on exemption
from registration thereunder. As of December 31, 2011,
our February 2015 Notes aggregate principal outstanding was
$180.0 million.
As
of December 31, 2011, our February 2015 Notes
unamortized issuance costs, included as a component of Other
assets on the Consolidated Balance Sheets, were
$3.2 million. As of December 31, 2011, the unamortized
discount on our February 2015 Notes was $2.3 million. The
issuance cost and discount are being amortized to interest
expense over the term of our February 2015 Notes, with a
remaining amortization period of approximately 3.2
years.
In
January and February 2012, we completed exchange transactions
where we exchanged our February 2015 Notes for our new 2.875%
Series 2012 Convertible Senior Notes due February 15, 2015
(Series 2012 Notes). For further information regarding the
Series 2012 Notes, see Note 19.
2012
Notes Retirement
Our
2012 Notes of $133.5 million aggregate principal were fully
retired at June 30, 2011, at a redemption price of 100.29% of
principal for aggregate consideration of $133.9 million plus
interest of $1.0 million. We recorded a net loss of $0.8
million from the redemption of the debt.
In
2010, we exchanged $92.0 million in aggregate principal of
our 2012 Notes for February 2015 Notes. In addition, we
repurchased $2.5 million aggregate principal value of our
2012 Notes at a discount of 0.5% to face value in an open
market transaction for aggregate consideration of $2.5
million in cash, plus accrued interest. Also in 2010, certain
holders of the 2012 Notes converted an aggregate of $10,000
principal of our 2010 Notes into 1,283 shares of common
stock.
In
2009, the Company repurchased $22.0 million aggregate
principal of our 2012 Notes, for aggregate consideration of
$21.0 million in cash, plus accrued interest. We recorded a
net gain of $0.8 million from the redemption of the
debt.
2023
Notes Retirement
As
of December 31, 2010, our 2023 Notes were fully retired.
In 2010, $111.7 million aggregate principal of our 2023 Notes
were converted into 20.0 million shares of common stock,
and we recorded a $2.4 million loss on the induced conversion
to shares of common stock. Additionally, $88.4 million
aggregate principal of our 2023 Notes were redeemed for
$104.6 million. In 2009, we repurchased $50.0 million
aggregate principal of our 2023 Notes, for aggregate
consideration of $49.0 million in cash, plus accrued interest
and recorded a net gain of $0.7 million.
Non-recourse
Notes
In
November 2009, we completed a $300 million
securitization transaction in which we monetized 60% of the
net present value of the estimated five year royalties from
sales of Genentech products (the Genentech Royalties)
including Avastin®,
Herceptin®,
Lucentis®,
Xolair®
and future products, if any, under which Genentech may take a
license under our related agreements with Genentech. Our QHP
PhaRMASM
Senior Secured Notes due 2015 (Non-recourse Notes) bear
interest at 10.25% per annum and were issued in a
non-registered offering by QHP, a Delaware limited liability
company, and a newly formed, wholly-owned subsidiary of PDL.
Concurrent with the securitization transaction and under the
terms of a purchase and sale agreement, we sold, transferred,
conveyed, assigned, contributed and granted to QHP, certain
rights under our non-exclusive license agreements with
Genentech including the right to receive the Genentech
Royalties in exchange for QHP’s proceeds from our
Non-recourse Notes issuance. Once all obligations on our
Non-recourse Notes have been paid in full, including all
other sums payable under the indenture, the indenture shall
cease to be of further effect and all of the security
interests in the collateral shall terminate, including the
pledge by PDL to the trustee of its equity interest in QHP.
At such point, there will be no further restrictions on the
Genentech Royalties and PDL shall be free to either keep them
in QHP, transfer them back to PDL or to further dispose or
monetize them.
The
Genentech Royalties and other payments, if any, that QHP will
be entitled to receive under the agreements with Genentech,
together with any funds made available from certain accounts
of QHP, will be the sole source of payment of principal and
interest on our Non-recourse Notes, which will be secured by
a continuing security interest granted by QHP in its rights
to receive payments under such agreements and all of its
other assets and a pledge by PDL of its equity ownership
interest in QHP. Our Non-recourse Notes may be redeemed at
any time prior to maturity, in whole or in part, at the
option of QHP at a make-whole redemption price. As of
December 31, 2011, the remaining principal balance was $93.4
million,
As
of December 31, 2011, the remaining unamortized issuance
costs were $1.2 million, and are included as a component
of Prepaid and other current assets on the Consolidated
Balance Sheets. These costs are being amortized to interest
expense using the effective interest method over the
estimated repayment period, or approximately three
years.
As
of December 31, 2011, PDL was in compliance with all
applicable debt covenants, and embedded features of all debt
agreements were evaluated and did not need to be accounted
for separately.
As
of December 31, 2011, the future minimum principal
payments under our February 2015 Notes, our May 2015 Notes
and our Non-recourse Notes were:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for long-term debt. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 13 - Other Long-Term Liabilities
|
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities Disclosure [Text Block] |
13.
Other Long-Term Liabilities
In
connection with the Spin-Off, we entered into amendments to
the leases for our former facilities in Redwood City,
California, under which Facet was added as a co-tenant under
the leases, and a Co-Tenancy Agreement, under which Facet
agreed to indemnify us for all matters related to the leases
attributable to the period after the Spin-Off date. Should
Facet default under its lease obligations, we would be held
liable by the landlord as a co-tenant and, thus, we have in
substance guaranteed the payments under the lease agreements
for the Redwood City facilities. As of December 31,
2011, the total lease payments for the duration of the
guarantee, which runs through December 2021, are
approximately $110.8 million. We would also be responsible
for lease-related costs including utilities, property taxes
and common area maintenance which may be as much as the
actual lease payments if Facet were to default. In April
2010, Abbott acquired Facet and later renamed the company
Abbott Biotherapeutics Corp.
As
of December 31, 2011 and 2010, we had a liability of
$10.7 million on our Consolidated Balance Sheets for the
estimated fair value of this guarantee. In future periods, we
may increase the recorded liability for this obligation if we
conclude that a loss, which is larger than the amount
recorded, is both probable and estimable.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for other liabilities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 14 - Stock-Based Compensation
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Disclosure of Compensation Related Costs, Share-based Payments [Text Block] |
14.
Stock-Based Compensation
We
recognize compensation expense, using a fair-value based
method, for costs associated with all share-based awards
issued to our directors, employees and outside consultants
under our stock plan. The value of the portion of the award
that is ultimately expected to vest is recognized as expense
on a straight-line basis over the requisite service periods
in our Consolidated Statements of Income.
We
have adopted the simplified method to calculate the beginning
balance of the additional paid-in capital (APIC) pool of the
excess tax benefit and to determine the subsequent effect on
the APIC pool and Consolidated Statements of Cash Flows of
the tax effects of employee stock-based compensation awards
that were outstanding upon our adoption.
We
calculate stock-based compensation expense based on the
number of awards ultimately expected to vest, net of
estimated forfeitures. We estimate forfeiture rates at the
time of grant and revise such rates, if necessary, in
subsequent periods if actual forfeitures differ from those
estimates. The stock-based compensation expense was
determined using the Black-Scholes option valuation
model.
Stock-based
compensation expense for directors and employees for the
years ended December 31, 2011, 2010 and 2009, was $337,000,
$662,000 and $773,000, respectively.
The
stock-based compensation expense related to non-employees for
the years ended December 31, 2011, 2010 and 2009, was
$50,000, zero, and $48,000, respectively.
Stock-Based
Incentive Plans
We
currently have one active stock-based incentive plan under
which we may grant stock-based awards to our employees,
directors and consultants.
The
total number of shares of common stock authorized for
issuance, shares of common stock issued upon exercise of
options or grant of restricted stock, shares of common stock
subject to outstanding awards and available for grant under
this plan as of December 31, 2011, is:
Under
our 2005 Equity Incentive Plan, we are authorized to issue a
variety of incentive awards, including stock options, stock
appreciation rights, restricted stock awards, restricted
stock unit awards, performance share and performance unit
awards, deferred compensation awards and other stock-based or
cash-based awards.
In
2009, our Compensation Committee terminated the 1991
Nonstatutory Stock Option Plan. Additionally our Compensation
Committee terminated the 1999 Outside Director Stock Option
Plan, the 1999 Nonstatutory Stock Option Plan and the
2002 Outside Directors Stock Option Plan, subject to any
outstanding options. Also in June 2009, our stockholders
approved amendments to the Company’s 2005 Equity
Incentive Plan to expand persons eligible to participate in
the plan to include our outside directors.
Stock
Option Activity
A
summary of our stock option activity is presented
below:
As
of December 31, 2011, the aggregate intrinsic value of
our outstanding and exercisable stock options was $45,000 and
the weighted-average remaining contractual life was 2.33
years. The aggregate intrinsic value represents the total
pre-tax intrinsic value, based on the closing prices of our
common stock of $6.20 on December 31, 2011, which would
have been received by the option holders had option holders
exercised their options as of that date. In connection with
the Spin-Off of Facet in December 2008, we terminated
substantially all employees. As a result, approximately
4 million options with an average exercise price of
$17.96 were forfeited during the year ended December 31,
2009. All stock options were fully vested in 2010.
Additional
information regarding our options exercised is set forth
below:
Restricted
Stock
Restricted
stock has the same rights as other issued and outstanding
shares of the Company’s common stock including, in some
cases, the right to accrue dividends, and are held in escrow
until the award vests. The compensation expense related to
these awards is determined using the fair market value of the
Company’s common stock on the date of the grant, and
the compensation expense is recognized over the vesting
period. Restricted stock awards typically vest over twelve to
twenty-four months. In addition to service requirements,
vesting of restricted stock awards, may be subject to the
achievement of specified performance goals set by the
Compensation Committee of the Company’s Board of
Directors. If the performance goals are not met, no
compensation expense is recognized and any previously
recognized compensation expense is reversed.
A
summary of our restricted stock activity is presented
below:
Stock-based
compensation expense associated with our restricted stock for
the years ended December 31, 2011, 2010 and 2009, was
$0.4 million, $0.6 million and $0.5 million, respectively. As
of December 31, 2011, the aggregate intrinsic value of
non-vested restricted stock was $0.8 million. Total
unrecognized compensation costs associated with non-vested
restricted stock as of December 31, 2011, was $0.5
million, excluding forfeitures, which we expect to recognize
over a weighted-average period of ten months.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 15 - Cash Dividends
|
12 Months Ended |
|---|---|
|
Dec. 31, 2011
|
|
| Stockholders' Equity Note Disclosure [Text Block] |
15.
Cash Dividends
On
January 18, 2012, our board of directors declared that
the regular quarterly dividends to be paid to our
stockholders in 2012 will be $0.15 per share of
common stock, payable on March 14,
June 14, September 14 and December 14
of 2012 to stockholders of record on March 7,
June 7, September 7 and December 7 of 2012,
the record dates for each of the dividend payments,
respectively.
On
February 25, 2011, our board of directors declared
regular quarterly dividends of $0.15 per share of common
stock, which were paid on March 15,
June 15, September 15 and December 15 of
2011 to stockholders of record on March 8,
June 8, September 8 and December 8 of
2011, the record dates for each of the dividend payment
dates, respectively. We paid $83.8 million in dividends in
2011.
In
January 2010, our board of directors declared two special
cash dividends of $0.50 per share of common stock payable on
April 1, 2010, and October 1, 2010. We paid $59.9
million to our stockholders on April 1, 2010, and $69.8
million to our stockholders on October 1, 2010. As of
December 31, 2010, we had $20,000 accrued in other
accrued liabilities for estimated dividends payable on
unvested restricted stock.
|
| X | ||||||||||
|
- Definition
The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 16 - Customer Concentration
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Concentration Risk Disclosure [Text Block] |
16.
Customer Concentration
The
percentage of total revenue earned from licensees net sales,
which individually accounted for 10% or more of our total
revenues:
Total
revenues by geographic area are based on the country of
domicile of the counterparty to the agreement:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 17 - Income Taxes
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Income Tax Disclosure [Text Block] |
17.
Income Taxes
The
provision for income taxes for the years ended
December 31, 2011, 2010 and 2009, consisted of the
following:
A
reconciliation of the income tax provision computed using the
U.S. statutory federal income tax rate compared to the income
tax provision for income included in the Consolidated
Statements of Income is:
Deferred
tax assets and liabilities are determined based on the
differences between financial reporting and income tax bases
of assets and liabilities, as well as net operating loss
carryforwards and are measured using the enacted tax rates
and laws in effect when the differences are expected to
reverse. The significant components of our net deferred tax
assets and liabilities are:
As
of December 31, 2011 and 2010, we had federal net
operating loss carryforwards of $42.9 million and $44.7
million, respectively. The federal net operating loss
carryforwards will expire in the year 2023, if not used. In
addition, as we moved our entire operations outside of
California in 2008, it is unlikely that we will realize any
future benefit from any state net operating loss and credit
carryforwards. The net operating loss carryforwards which
resulted from exercises of stock options were not recorded on
the Consolidated Balance Sheet. Instead, such unrecognized
deferred tax benefits were accounted for as a credit to
additional paid-in capital and were realized through a
reduction in taxes payable.
Use
of the federal net operating loss and tax credit
carryforwards may be subject to a substantial annual
limitation due to the “change in ownership”
provisions of the Internal Revenue Code of 1986. The annual
limitation may result in the expiration of net operating
losses and credits before they are used. We have an annual
limitation on the use of our federal operating losses of $1.8
million for each of the years ended December 31, 2012 to
2022, and $1.3 million for the year ended December 31,
2023. As of December 31, 2011, we estimate that at least
$22.0 million of the $42.9 million of federal net operating
loss carryforwards will expire prior to their use due to
change of ownership provisions.
During
the year ended December 31, 2011, we recorded no change
in our liability associated with uncertain tax positions. A
reconciliation of our unrecognized tax benefits, excluding
accrued interest and penalties, for 2011 and 2010 is:
The
future impact of the unrecognized tax benefit of $23.1
million, if recognized, is as follows: $12.2 million would
affect the effective tax rate and $10.9 million would result
in adjustments to deferred tax assets and corresponding
adjustments to the valuation allowance.
Estimated
interest and penalties associated with unrecognized tax
benefits increased income tax expense in the Consolidated
Statements of Income by $0.5 million during the year ended
December 31, 2011, and decreased income tax expense by
$26,000 and $0.4 million during the years ended
December 31, 2010 and 2009, respectively. In general,
our income tax returns are subject to examination by U.S.
federal, state, and local tax authorities for tax years 1995
forward. The IRS is currently examining our 2008 tax return.
We are also currently under income tax examination in the
state of California for tax years 2008 and 2009.
Although
the timing of the resolution of income tax examinations is
highly uncertain, and the amounts ultimately paid, if
any, upon resolution of the issues raised by the taxing
authorities may differ materially from the amounts accrued
for each year, we do not anticipate any material change to
the amount of our unrecognized tax benefits over the next 12
months.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 18 - Legal Proceedings
|
12 Months Ended |
|---|---|
|
Dec. 31, 2011
|
|
| Legal Matters and Contingencies [Text Block] |
18.
Legal Proceedings
Resolution
of Challenges against the Queen et al. Patents in the United
States and Europe
MedImmune
Settlement
On February 10, 2011, we entered into a definitive
settlement agreement with MedImmune, LLC (MedImmune)
resolving all legal disputes with them, including those
relating to MedImmune’s product Synagis® and
PDL’s patents known as the Queen et al. patents. Under
the settlement agreement, PDL paid MedImmune $65.0 million on
February 15, 2011, and an additional $27.5 million on
February 9, 2012, for a total of $92.5 million. No
further payments will be owed by MedImmune to PDL under its
license to the Queen et al. patents as a result of past or
future Synagis sales and MedImmune will cease any support,
financial or otherwise, of any party involved in the appeal
proceeding before the European Patent Office (EPO) relating
to the opposition against European Patent No. 0 451 216B (the
‘216B Patent) including the opposition owned by
BioTransplant Incorporated (BioTransplant).
Settlement
with UCB
On
February 2, 2011, we reached a settlement with UCB
Pharma S.A. (UCB). Under the settlement agreement, PDL
provided UCB a covenant not to sue UCB for any royalties
regarding UCB’s Cimzia®
product under the Queen et al. patents in return for a lump
sum payment of $10 million to PDL and termination of pending
patent interference proceedings before the U.S. Patent and
Trademark office (PTO) involving our U.S. Patent
No. 5,585,089 patent (the ‘089 Patent) and our
U.S. Patent No. 6.180.370 (the ‘370 Patent) in
PDL’s favor. UCB also agreed to formally withdraw its
opposition appeal challenging the validity of the ‘216B
Patent.
Settlement
with Novartis
On
February 25, 2011, we reached a settlement with Novartis AG
(Novartis). Under the settlement agreement, PDL agreed to
dismiss its claims against Novartis in its action in Nevada
state court which also includes Genentech, Inc. (Genentech)
and F. Hoffman Roche Ltd (Roche) as defendants. Novartis
agreed to withdraw its opposition appeal in the EPO
challenging the validity of the ‘216B Patent. Under the
settlement agreement with Novartis, we will pay Novartis
certain amounts based on net sales of Lucentis made by
Novartis during calendar year 2011 and beyond. The settlement
does not affect our claims against Genentech and Roche in the
Nevada state court action. We do not currently expect such
amount to materially impact our total annual revenues.
European
Opposition to ‘216B Patent
Termination
of European Opposition to ‘216B Patent
Pursuant
to our settlements with UCB, MedImmune and Novartis, and as a
result of our acquisition of BioTransplant and subsequent
withdrawal of BioTransplant’s appeal, all of the active
appellants in the EPO opposition have formally withdrawn
their participation in the appeal proceeding. Accordingly,
the EPO has cancelled the appeal proceeding and terminated
the opposition proceeding in its entirety, with the result
that the 2007 EPO decision upholding the claims of our
‘216B Patent as valid will become the final decision of
the EPO. In the year ending December 31, 2011,
approximately 33% of our royalty revenues were derived from
sales of products that were made in Europe and sold outside
of the United States.
Genentech
/ Roche Matter
Communications
with Genentech regarding European SPCs
In
August 2010, we received a letter from Genentech, sent on
behalf of Roche and Novartis, asserting that Avastin,
Herceptin, Lucentis and Xolair (the Genentech Products) do
not infringe the supplementary protection certificates (SPCs)
granted to PDL by various countries in Europe for each of the
Genentech Products and seeking a response from PDL to these
assertions. Genentech did not state what actions, if any, it
intends to take with respect to its assertions. PDL’s
SPCs were granted by the relevant national patent offices in
Europe and specifically cover the Genentech Products. The
SPCs covering the Genentech Products effectively extend our
European patent protection for the ‘216B Patent
generally until December 2014, except that the SPCs for
Herceptin will generally expire in July 2014.
Genentech’s
letter does not suggest that the Genentech Products do not
infringe PDL’s U.S. patents to the extent that such
Genentech Products are made, used or sold in the United
States (U.S.-based Sales). Genentech’s quarterly
royalty payments received in August and November of 2010
after receipt of the letter included royalties generated on
all worldwide sales of the Genentech Products.
If
Genentech is successful in asserting this position, then
under the terms of our license agreements with Genentech, it
would not owe us royalties on sales of the Genentech Products
that are both manufactured and sold outside of the United
States. Royalties on sale of the Genentech Products that are
made and sold outside of the United States (ex-U.S.-based
Manufacturing and Sales) accounted for approximately 33% of
our royalty revenues for the year ended December 31,
2011. Based on announcements by Roche regarding moving more
manufacturing outside of the United States, we expect this
amount to increase in the future.
We
believe that the SPCs are enforceable against the Genentech
Products, that Genentech’s letter violates the terms of
the 2003 settlement agreement and that Genentech owes us
royalties on sales of the Genentech Products on a worldwide
basis. We intend to vigorously assert our SPC-based patent
rights.
Nevada
Litigation with Genentech, Roche and Novartis in Nevada State
Court
In
August 2010, we filed a complaint in the Second Judicial
District of Nevada, Washoe County, naming Genentech, Roche
and Novartis as defendants. We intend to enforce our rights
under our 2003 settlement agreement with Genentech and are
seeking an order from the court declaring that Genentech is
obligated to pay royalties to us on ex-U.S.-based
Manufacturing and Sales of the Genentech Products.
The
2003 settlement agreement was entered into as part of a
definitive agreement resolving intellectual property disputes
between the two companies at that time. The agreement limits
Genentech’s ability to challenge infringement of our
patent rights and waives Genentech’s right to challenge
the validity of our patent rights. Certain breaches of the
2003 settlement agreement as alleged by our complaint require
Genentech to pay us liquidated and other damages of
potentially greater than one billion dollars. This amount
includes a retroactive royalty rate of 3.75% on past
U.S.-based Sales of the Genentech Products and interest,
among other items. We may also be entitled to either
terminate our license agreements with Genentech or be paid a
flat royalty of 3.75% on future U.S.-based Sales of the
Genentech Products.
In
November 2010, Genentech and Roche filed a motion to
dismiss our complaint against them in which we seek to
enforce our rights under the 2003 settlement agreement with
Genentech. Genentech and Roche's motions to dismiss under
Nevada Rule of Civil Procedure 12(b)(5) alleged that all of
our claims for relief relating to the 2003 settlement
agreement should be dismissed because the 2003 settlement
agreement applies only to our U.S. patents. In addition,
Roche filed a separate motion to dismiss our complaint
under Nevada Rule of Civil Procedure 12(b)(2) on the ground
that the Nevada court lacks personal jurisdiction over
Roche. On July 7, 2011, the Second Judicial District Court
of Nevada ruled in favor of us on the two motions to
dismiss filed by Genentech and Roche. The court denied
Genentech and Roche's motion to dismiss four of our five
claims for relief and, further, denied Roche's separate
motion to dismiss for lack of personal jurisdiction. The
court dismissed one of our claims that Genentech committed
a bad-faith breach of the covenant of good faith and fair
dealing stating that, based on the current state of the
pleadings, no "special relationship" had been established
between Genentech and us as required under Nevada law. On
November 1, 2011, the Nevada court issued an order
accepting Roche’s stipulation of waiver to its
personal jurisdiction defense. As a result of the order,
Roche is foreclosed from reliance on lack of personal
jurisdiction in defending against our claims.
On
February 25, 2011, we reached a settlement with Novartis
under which, among other things, we agreed to dismiss our
claims against Novartis in the action in Nevada state court
against Genentech, Roche and Novartis. Genentech and Roche
continue to be parties to the Nevada suit.
|
| X | ||||||||||
|
- Definition
The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies. No definition available.
|
|
Note 19 - Subsequent Event
|
12 Months Ended |
|---|---|
|
Dec. 31, 2011
|
|
| Subsequent Events [Text Block] |
19.
Subsequent Event
In
January 2012, we completed an exchange transaction where we
exchanged and subsequently retired approximately $169.0
million aggregate principal amount, representing
approximately 93.9%, of our 2.875% Convertible Senior Notes
due February 15, 2015 (February 2015 Notes), for
approximately $169.0 million aggregate principal amount of
new 2.875% Series 2012 Convertible Senior Notes due February
15, 2015 (Series 2012 Notes), plus a cash payment of $5.00
for each $1,000 principal amount tendered for a total cash
incentive payment of approximately $0.8 million. In February
2012, we entered into separate privately negotiated exchange
agreements under which we retired an additional $10.0 million
aggregate principal amount of our February 2015 Notes for
$10.0 million aggregate principal amount of our Series 2012
Notes. Following settlement of the exchanges on February 2,
2012, $1.0 million of our February 2015 Notes and $179.0
million of our Series 2012 Notes were outstanding. Like our
May 2015 Notes, our Series 2012 Notes net share settle. The
effect of issuing $179.0 million aggregate principal of our
Series 2012 Notes with the net share settle feature in
exchange for our February 2015 Notes was the reduction of
27.8 million shares of potential dilution to our
stockholders.
Our
Series 2012 Notes bear interest at a rate of 2.875% per
annum, payable semiannually in arrears on February 15 and
August 15 of each year, beginning on February 15, 2012. The
conversion rate for our new Series 2012 Notes is 155.396
shares of the Company’s common stock per $1,000
principal amount, which is equivalent to an initial
conversion price of approximately $6.44 per share of common
stock.
|
| X | ||||||||||
|
- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. No definition available.
|
|
Note 20 - Quarterly Financial Data (Unaudited)
|
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Quarterly Financial Information [Text Block] |
20.
Quarterly Financial Data (Unaudited)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Accounting Policies, by Policy (Policies)
|
12 Months Ended |
|---|---|
|
Dec. 31, 2011
|
|
| Basis of Accounting [Text Block] | Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and under the rules and regulations of the Securities and Exchange Commission (SEC). |
| Consolidation, Policy [Policy Text Block] | Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, QHP Royalty Sub LLC (QHP). All material intercompany balances and transactions are eliminated in consolidation. We prepare our consolidated financial statements in accordance with the SEC and GAAP and include all adjustments of a normal recurring nature that are necessary to fairly present our consolidated results of operations, financial position and cash flows for all periods presented. |
| Use of Estimates, Policy [Policy Text Block] | Management Estimates The preparation of financial statements in conformity with GAAP requires the use of management's estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. |
| Segment Reporting, Policy [Policy Text Block] | Segment Disclosures We are required to report operating segments and make related disclosures about our products, services, geographic areas and major customers. Our chief operating decision-maker consists of our executive management. Our chief operating decision-maker reviews our operating results and operating plans and makes resource allocation decisions on a company-wide or aggregate basis. As of December31, 2011, we operated as one segment. Our operations and facilities are located in Incline Village, Nevada. |
| Cash and Cash Equivalents, Policy [Policy Text Block] | Cash Equivalents and Investments We consider all highly liquid investments with initial maturities of three months or less at the date of purchase to be cash equivalents. We place our cash, cash equivalents and investments with high credit quality financial institutions and in U.S. government securities, U.S.government agency securities and investment grade corporate debt securities and, by policy, limit the amount of credit exposure in any one financial instrument. Available-for-sale securities are reported at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income (loss). See Note 5. |
| Fair Value of Financial Instruments, Policy [Policy Text Block] | Fair Value Measurements The fair value of our financial instruments are estimates of the amounts that would be received if we were to sell an asset or we paid to transfer a liability in an orderly transaction between market participants at the measurement date or exit price. The assets and liabilities are categorized and disclosed in one the following three categories: Level 1 - based on quoted market prices in active markets for identical assets and liabilities; Level 2 - based on quoted market prices for similar assets and liabilities, using observable market based inputs or unobservable market based inputs corroborated by market data, and Level 3 - based on unobservable inputs using management's best estimate and assumptions when inputs are unavailable. As of December 31, 2011 and 2010, we had no Level 3 assets or liabilities. We do not estimate the fair value of our royalty assets for financial statement reporting purposes. |
| Foreign Currency Transactions and Translations Policy [Policy Text Block] | Foreign Currency Hedging We hedge certain Eurodollar currency exposures related to our licensees' product sales with Eurodollar forward contracts and Eurodollar option contracts (collectively, Eurodollar contracts). In general, these contracts are intended to offset the underlying Eurodollar market risk in our royalty revenues. Our exposure to credit risk from these contracts is a function of foreign currency exchange rates and, therefore, varies over time. We transact with major banks to limit the credit risk that our counterparty may be unable to perform and monitor the exposure in the context of current market conditions. We mitigate the risk of loss by entering into a netting agreement with our counterparty that provides for aggregate net settlement of all of the Eurodollar contracts should our counterparty default on the contracts prior to contract settlement. Therefore, our overall risk of loss in the event of counterparty default is limited to the net amount of any unrecognized gains or losses on outstanding contracts at the date of default. We do not enter into speculative foreign currency transactions. We have designated the Eurodollar contracts as cash flow hedges. At the inception of the hedging relationship and on a quarterly basis, we assess hedge effectiveness. The aggregate unrealized gain or loss on the effective component of our Eurodollar contracts, net of estimated taxes, is recorded in stockholders' deficit as accumulated other comprehensive income (loss). Gains or losses on cash flow hedges are recognized as royalty revenue in the same period that the hedged transaction, royalty revenue, impacts earnings. |
| Revenue Recognition, Policy [Policy Text Block] | Revenue Recognition Royalty Revenues Under most of our patent license agreements, we receive royalty payments based upon our licensees' net sales of covered products. Generally, under these agreements we receive royalty reports from our licensees approximately one quarter in arrears, that is, generally in the second month of the quarter after the licensee has sold the royalty-bearing product. We recognize royalty revenues when we can reliably estimate such amounts and collectability is reasonably assured. As such, we generally recognize royalty revenues in the quarter reported to us by our licensees, that is, royalty revenues are generally recognized one quarter following the quarter in which sales by our licensees occurred. Under this accounting policy, the royalty revenues we report are not based upon our estimates and such royalty revenues are typically reported in the same period in which we receive payment from our licensees. We may also receive minimal annual maintenance fees from licensees of our Queen et al. patents prior to patent expiry as well as periodic milestone payments. We have no performance obligations with respect to such fees. Maintenance fees are recognized as they are due and when payment is reasonably assured. Total annual milestone payments in each of the last several years have been less than 1% of total revenue. |
| Property, Plant and Equipment, Policy [Policy Text Block] | Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization were computed using the straight-line method over the following estimated useful lives: |
| X | ||||||||||
|
- Definition
The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). No definition available.
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for determining the fair value of financial instruments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for property, plant and equipment which may include the basis of such assets, depreciation methods used and estimated useful lives, the entity's capitalization policy, including its accounting treatment for costs incurred for repairs and maintenance activities, whether such asset balances include capitalized interest and the method by which such is calculated, how disposals of such assets are accounted for and how impairment of such assets is assessed and recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for segment reporting. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 3 - Net Income per Share (Tables)
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Calculation of Numerator and Denominator in Earnings Per Share [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of the numerators and the denominators of the basic and diluted per-share (or per-unit) computations for income from continuing operations, including the effect that has been given to preferred dividends. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 4 - Fair Value Measurements (Tables)
|
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 5 - Cash Equivalents, Short-term and Long-term Investments (Tables)
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Available-for-sale Securities Reconciliation [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fair Value, by Balance Sheet Grouping [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments Classified by Contractual Maturity Date [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments, assets, and liabilities. Such certain disclosures about the financial instruments, assets, and liabilities include: (1) the fair value of the required items together with their carrying amounts (as appropriate) and (2) the methodology and assumptions used in developing such estimates of fair value. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments. No definition available.
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value. No definition available.
|
|
Note 6 - Foreign Currency Hedging (Tables)
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Derivative Instruments [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the carrying amounts of prepaid and other current assets. No definition available.
|
|
Note 8 - Property and Equipment (Tables)
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Property, Plant and Equipment [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of the useful life and salvage value of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 9 - Other Assets (Tables)
|
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Other Assets, Noncurrent [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of noncurrent assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 10 - Accrued Liabilities (Tables)
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Accrued Liabilities [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of the components of accrued liabilities. No definition available.
|
|
Note 11 - Commitments and Contingencies (Tables)
|
12 Months Ended | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||
| Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] |
|
||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 12 - Convertible and Non-Recourse Notes (Tables)
|
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Debt [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Interest Expense on May 2015 Notes [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Maturities of Long-term Debt [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of notes including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation. No definition available.
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 13 - Other Long-Term Liabilities (Tables)
|
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Other Assets and Other Liabilities [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of other assets and other liabilities not separately disclosed on the balance sheet. No definition available.
|
|
Note 14 - Stock-Based Compensation (Tables)
|
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Common Stock Activity Available Under Share Based Compensation Plans [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Cash Proceeds Received from Share-based Payment Awards [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the amount of cash proceeds received from the exercise of stock options and similar instruments granted under share-based payment arrangements and the tax benefit realized from stock options exercised during the period. Disclosure may also include the intrinsic value of stock options exercised during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 16 - Customer Concentration (Tables)
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Entity Wide Information Revenue From External Customers by Products and Services [TableTextBlock] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. No definition available.
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 17 - Income Taxes (Tables)
|
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Deferred Tax Assets and Liabilities [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Income Tax Contingencies [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities (i.e., uncertain tax positions) and other types of income tax contingencies, including: (1) the policy on classification of interest and penalties; (2) a tabular reconciliation of the total amounts of unrecognized tax benefits at the beginning and end of the period; the total amount(s) of: (3) unrecognized tax benefits that, if recognized, would affect the effective tax rate, and (4) interest and penalties recognized in each of the income statement and balance sheet; (5) for positions for which it is reasonably possible that the total amounts unrecognized will significantly change within 12 months of the reporting date the: (i) nature of the uncertainty, (ii) nature of the event that could occur that would cause the change, and (iii) an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made; and (6) a description of tax years that remain subject to examination by major tax jurisdictions. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 20 - Quarterly Financial Data (Unaudited) (Tables)
|
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Quarterly Financial Information [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of the quarterly financial data in the annual financial statements. The disclosure includes financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income (loss) before extraordinary items and cumulative effect of a change in accounting principle and earnings per share data. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 1 - Organization and Business (Detail) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Royalty Revenue | $ 351,641 | $ 343,475 | $ 305,049 |
| X | ||||||||||
|
- Definition
Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 2 - Summary of Significant Accounting Policies (Detail) (USD $)
|
9 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2010
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Maximum total annual milestone payments | 1.00% | |||
| Comprehensive Income (Loss) Note [Text Block] | Comprehensive Income (Loss) Comprehensive income (loss) comprises net income adjusted for other comprehensive income (loss), which includes the changes in unrealized gains and losses on Eurodollar contracts and changes in unrealized gains and losses on our investments in available-for-sale securities, if any, which are excluded from our net income. The components and accumulated balances of comprehensive income (loss) were: | |||
| Derivative Instruments, Loss Recognized in Other Comprehensive Income (Loss), Effective Portion | $ 1,900,000 | $ 0 | ||
| Unrealized Gain (Loss) on Cash Flow Hedging Instruments | 3,200,000 | |||
| Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax | $ (1,000) | $ 29,000 | $ 1,000 | $ 0 |
| Description of New Accounting Pronouncements Not yet Adopted [Text Block] | Recent Accounting Pronouncements In June 2011, the Financial Accounting Standards Board (FASB) issued accounting standard update (ASU) 2011-05, eliminating the option to present the components of other comprehensive income as part of the statement of changes in stockholders' equity. The update requires presentation for items of net income and other comprehensive income either in one continuous statement or in two separate, but consecutive, statements. Additionally, this ASU includes a new requirement to show reclassification adjustments from other comprehensive income to net income on the face of the statement. Except for, the new requirement to show reclassification adjustments from other comprehensive income to income on the face of the income statement, this guidance is required for our first quarter of 2012 with retrospective application also required. We do not expect this guidance to have a material impact on our financial statements. | |||
|
Leaseholds and Leasehold Improvements [Member]
|
||||
| Property, Plant and Equipment, Estimated Useful Lives | Shorterofassetlifeortermoflease | |||
|
Computer and Office Equipment [Member]
|
||||
| Property, Plant and Equipment, Useful Life, Average | 3 | |||
|
Furniture and Fixtures [Member]
|
||||
| Property, Plant and Equipment, Useful Life, Average | 7 | |||
| X | ||||||||||
|
- Definition
The maximum total annual milestone payments from licensees. No definition available.
|
| X | ||||||||||
|
- Definition
The entire disclosure for comprehensive income. Includes, but is not limited to, the following: 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income. Components of comprehensive income include: (1) foreign currency translation adjustments; (2) gains (losses) on foreign currency transactions that are designated as, and are effective as, economic hedges of a net investment in a foreign entity; (3) gains (losses) on intercompany foreign currency transactions that are of a long-term-investment nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements; (4) change in the market value of a futures contract that qualifies as a hedge of an asset reported at fair value; (5) unrealized holding gains (losses) on available-for-sale securities and that resulting from transfers of debt securities from the held-to-maturity category to the available-for-sale category; (6) a net loss recognized as an additional pension liability not yet recognized as net periodic pension cost; and (7) the net gain (loss) and net prior service cost or credit for pension plans and other postretirement benefit plans. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The effective portion of losses on derivative instruments designated and qualifying as hedging instruments that was recognized in other comprehensive income during the current period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The entire disclosure for a new accounting pronouncement that has been issued but not yet adopted. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Appreciation or loss in value (before reclassification adjustment) of the total of unsold securities during the period being reported on, net of tax. Reclassification adjustments include: (1) the unrealized holding gain (loss), net of tax, at the date of the transfer for a debt security from the held-to-maturity category transferred into the available-for-sale category. Also includes the unrealized gain (loss) at the date of transfer for a debt security from the available-for-sale category transferred into the held-to-maturity category; (2) the unrealized gains (losses) realized upon the sale of securities, after tax; and (3) the unrealized gains (losses) realized upon the write-down of securities, after tax. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The average useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. No definition available.
|
| X | ||||||||||
|
- Definition
Amount of unrealized gain (loss) related to derivatives designated as cash flow hedging instruments, recorded in results of operations to the extent that the cash flow hedge is determined to be ineffective. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 3 - Net Income per Share (Detail)
In Millions, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
|
Due 2012 [Member]
|
|||
| Debt Instrument, Interest Rate, Stated Percentage | 2.00% | ||
|
Stock Options [Member]
|
|||
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 0.2 | 0.3 | 2.5 |
|
Convertible May 2015 Notes [Member]
|
|||
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 13.3 | ||
|
Warrants [Member]
|
|||
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 13.3 | ||
|
Purchased Call Options [Member]
|
|||
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 13.3 | ||
|
Due February 2015 [Member]
|
|||
| Debt Instrument, Interest Rate, Stated Percentage | 2.875% | ||
|
Due 2023 [Member]
|
|||
| Debt Instrument, Interest Rate, Stated Percentage | 2.75% | ||
|
Due May 2015 [Member]
|
|||
| Debt Instrument, Interest Rate, Stated Percentage | 3.75% | ||
| X | ||||||||||
|
- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Interest rate stated in the contractual debt agreement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 3 - Net Income per Share (Detail) - Net Income Per Basic and Diluted Share (USD $)
In Thousands, unless otherwise specified |
2 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|
|
Feb. 29, 2012
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Net income (in Dollars) | $ 199,389 | $ 91,874 | $ 189,660 | |
| Add back interest expense for convertible notes, net of estimated tax of $3.0 million, $2.7 million, and $3.8 million for the years ended December 31, 2011, 2010 and 2009, respectively (see Note 12) (in Dollars) | 5,544 | 5,087 | 7,079 | |
| Income used to compute net income per diluted share (in Dollars) | $ 204,933 | $ 96,961 | $ 196,739 | |
| Total weighted-average shares used to compute net income per basic share | 139,663 | 126,578 | 119,402 | |
| Assumed conversion of debt notes (in shares) | 27,800 | |||
| Shares used to compute net income per diluted share | 177,441 | 178,801 | 184,400 | |
|
Stock Options [Member]
|
||||
| Incremental common shares attributable to share based payment arrangements | 13 | 9 | 18 | |
|
Restricted Stock [Member]
|
||||
| Incremental common shares attributable to share based payment arrangements | 25 | 103 | 42 | |
|
Due 2012 [Member]
|
||||
| Assumed conversion of debt notes (in shares) | 9,790 | 29,870 | 28,809 | |
|
Due February 2015 [Member]
|
||||
| Assumed conversion of debt notes (in shares) | 27,950 | 4,229 | ||
|
Due 2023 [Member]
|
||||
| Assumed conversion of debt notes (in shares) | 18,012 | 36,129 | ||
| X | ||||||||||
|
- Definition
Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The after-tax amount of interest recognized in the period associated with any convertible debt. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 3 - Net Income per Share (Detail) - Net Income Per Basic and Diluted Share (Parentheticals) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Estimated tax on interest expense on convertible notes | $ 3,000,000 | $ 2,700,000 | $ 3,800,000 |
| X | ||||||||||
|
- Definition
The estimated tax on interest expense recognized in the period associated with any convertible debt. No definition available.
|
|
Note 4 - Fair Value Measurements (Detail) - Assets and Liabilities Recorded at Fair Value (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2011
|
Dec. 31, 2010
|
|---|---|---|
| Assets: | ||
| Available for Sale Securities at Fair Value | $ 224,769 | $ 242,472 |
|
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
|
||
| Assets: | ||
| Available for Sale Securities at Fair Value | 163,368 | 203,318 |
|
Money Market Funds [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
|
||
| Assets: | ||
| Available for Sale Securities at Fair Value | 163,368 | 203,318 |
|
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
|
||
| Assets: | ||
| Available for Sale Securities at Fair Value | 20,434 | |
|
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
|
||
| Assets: | ||
| Available for Sale Securities at Fair Value | 44,877 | |
|
Corporate Debt Securities [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
|
||
| Assets: | ||
| Available for Sale Securities at Fair Value | 44,877 | 20,434 |
|
Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member]
|
||
| Assets: | ||
| Available for Sale Securities at Fair Value | 8,996 | 7,998 |
|
Commercial Paper [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
|
||
| Assets: | ||
| Available for Sale Securities at Fair Value | 8,996 | 7,998 |
|
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
|
||
| Assets: | ||
| Available for Sale Securities at Fair Value | 2,015 | 8,725 |
|
US Government Agencies Debt Securities [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
|
||
| Assets: | ||
| Available for Sale Securities at Fair Value | 2,015 | 8,725 |
|
US Treasury Securities [Member] | Fair Value, Inputs, Level 1 [Member]
|
||
| Assets: | ||
| Available for Sale Securities at Fair Value | 5,513 | 1,997 |
|
US Treasury Securities [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
|
||
| Assets: | ||
| Available for Sale Securities at Fair Value | 5,513 | 1,997 |
|
Derivative Financial Instruments, Assets [Member] | Fair Value, Inputs, Level 2 [Member]
|
||
| Assets: | ||
| Foreign currency hedge contracts | 6,838 | 17,763 |
|
Derivative Financial Instruments, Assets [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
|
||
| Assets: | ||
| Foreign currency hedge contracts | 6,838 | 17,763 |
|
Fair Value, Inputs, Level 1 [Member]
|
||
| Assets: | ||
| Total | 170,896 | 234,474 |
|
Fair Value, Inputs, Level 2 [Member] | Derivative Financial Instruments, Liabilities [Member]
|
||
| Assets: | ||
| Foreign currency hedge contracts | 9,783 | 12,810 |
|
Fair Value, Inputs, Level 2 [Member]
|
||
| Assets: | ||
| Total | 60,711 | 25,761 |
|
Estimate of Fair Value, Fair Value Disclosure [Member] | Derivative Financial Instruments, Liabilities [Member]
|
||
| Assets: | ||
| Foreign currency hedge contracts | 9,783 | 12,810 |
|
Estimate of Fair Value, Fair Value Disclosure [Member]
|
||
| Assets: | ||
| Total | $ 231,607 | $ 260,235 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
This element represents the aggregate of the assets reported on the balance sheet at period end measured at fair value by the entity. This element is intended to be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. No definition available.
|
| X | ||||||||||
|
- Definition
This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents Available-for-sale Securities which consist of all investments in certain debt and equity securities neither classified as trading or held-to-maturity securities. A debt security represents a creditor relationship with an enterprise. Debt securities include, among other items, US Treasury securities, US government securities, municipal securities, corporate bonds, convertible debt, commercial paper, and all securitized debt instruments. An equity security represents an ownership interest in an enterprise or the right to acquire or dispose of an ownership interest in an enterprise at fixed or determinable prices. Equity securities include, among other things, common stock, certain preferred stock, warrant rights, call options, and put options, but do not include convertible debt. An entity may opt to provide the reader with additional narrative text to better understand the nature of investments in debt and equity securities which are categorized as Available-for-sale. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents contracts related to the exchange of different currencies, including foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into and existing as of the balance sheet date. No definition available.
|
| X | ||||||||||
|
- Definition
This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents contracts related to the exchange of different currencies, including foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into and existing as of the balance sheet date. No definition available.
|
|
Note 5 - Cash Equivalents, Short-term and Long-term Investments (Detail) (USD $)
|
9 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2010
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax | $ (1,000) | $ 29,000 | $ 1,000 | $ 0 |
| X | ||||||||||
|
- Definition
Appreciation or loss in value (before reclassification adjustment) of the total of unsold securities during the period being reported on, net of tax. Reclassification adjustments include: (1) the unrealized holding gain (loss), net of tax, at the date of the transfer for a debt security from the held-to-maturity category transferred into the available-for-sale category. Also includes the unrealized gain (loss) at the date of transfer for a debt security from the available-for-sale category transferred into the held-to-maturity category; (2) the unrealized gains (losses) realized upon the sale of securities, after tax; and (3) the unrealized gains (losses) realized upon the write-down of securities, after tax. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 5 - Cash Equivalents, Short-term and Long-term Investments (Detail) - Available-for-Sale Debt Securities (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2011
|
Dec. 31, 2010
|
|---|---|---|
| Available for Sale Securities Amortized Cost | $ 224,725 | $ 242,474 |
| Available for Sale Securities Gross Unrealized Gains | 88 | 5 |
| Available for Sale Securities Gross Unrealized Losses | (44) | (7) |
| Available for Sale Securities Estimated Fair Value | 224,769 | 242,472 |
|
Money Market Funds [Member]
|
||
| Available for Sale Securities Amortized Cost | 163,368 | 203,318 |
| Available for Sale Securities Gross Unrealized Gains | 0 | 0 |
| Available for Sale Securities Gross Unrealized Losses | 0 | 0 |
| Available for Sale Securities Estimated Fair Value | 163,368 | 203,318 |
|
Corporate Debt Securities [Member]
|
||
| Available for Sale Securities Amortized Cost | 44,863 | 20,437 |
| Available for Sale Securities Gross Unrealized Gains | 57 | 2 |
| Available for Sale Securities Gross Unrealized Losses | (43) | (5) |
| Available for Sale Securities Estimated Fair Value | 44,877 | 20,434 |
|
Commercial Paper [Member]
|
||
| Available for Sale Securities Amortized Cost | 8,997 | 7,998 |
| Available for Sale Securities Gross Unrealized Gains | 0 | 0 |
| Available for Sale Securities Gross Unrealized Losses | (1) | 0 |
| Available for Sale Securities Estimated Fair Value | 8,996 | 7,998 |
|
US Government Agencies Debt Securities [Member]
|
||
| Available for Sale Securities Amortized Cost | 2,003 | 8,727 |
| Available for Sale Securities Gross Unrealized Gains | 12 | 0 |
| Available for Sale Securities Gross Unrealized Losses | 0 | (2) |
| Available for Sale Securities Estimated Fair Value | 2,015 | 8,725 |
|
US Treasury Securities [Member]
|
||
| Available for Sale Securities Amortized Cost | 5,494 | 1,994 |
| Available for Sale Securities Gross Unrealized Gains | 19 | 3 |
| Available for Sale Securities Gross Unrealized Losses | 0 | 0 |
| Available for Sale Securities Estimated Fair Value | $ 5,513 | $ 1,997 |
| X | ||||||||||
|
- Definition
This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents Available-for-sale Securities which consist of all investments in certain debt and equity securities neither classified as trading or held-to-maturity securities. A debt security represents a creditor relationship with an enterprise. Debt securities include, among other items, US Treasury securities, US government securities, municipal securities, corporate bonds, convertible debt, commercial paper, and all securitized debt instruments. An equity security represents an ownership interest in an enterprise or the right to acquire or dispose of an ownership interest in an enterprise at fixed or determinable prices. Equity securities include, among other things, common stock, certain preferred stock, warrant rights, call options, and put options, but do not include convertible debt. An entity may opt to provide the reader with additional narrative text to better understand the nature of investments in debt and equity securities which are categorized as Available-for-sale. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This item represents the gross unrealized gains for securities, at a point in time, which are categorized neither as held-to-maturity nor trading securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This item represents the gross unrealized losses for securities, at a point in time, which are categorized neither as held-to-maturity nor trading securities. No definition available.
|
|
Note 5 - Cash Equivalents, Short-term and Long-term Investments (Detail) - Available-For-Sale Securities Balance Sheet Classification (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2011
|
Dec. 31, 2010
|
|---|---|---|
| Cash equivalents | $ 165,367 | $ 205,817 |
| Short-term investments | 42,301 | 34,658 |
| Long-term investments | 17,101 | 1,997 |
| Total | $ 224,769 | $ 242,472 |
| X | ||||||||||
|
- Definition
This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents Available-for-sale Securities which consist of all investments in certain debt and equity securities neither classified as trading or held-to-maturity securities. A debt security represents a creditor relationship with an enterprise. Debt securities include, among other items, US Treasury securities, US government securities, municipal securities, corporate bonds, convertible debt, commercial paper, and all securitized debt instruments. An equity security represents an ownership interest in an enterprise or the right to acquire or dispose of an ownership interest in an enterprise at fixed or determinable prices. Equity securities include, among other things, common stock, certain preferred stock, warrant rights, call options, and put options, but do not include convertible debt. An entity may opt to provide the reader with additional narrative text to better understand the nature of investments in debt and equity securities which are categorized as Available-for-sale. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Company may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 5 - Cash Equivalents, Short-term and Long-term Investments (Detail) - Summary of Available-For-Sale Securities (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2011
|
Dec. 31, 2010
|
|---|---|---|
| Less than one year | $ 44,262 | $ 37,162 |
| Less than one year | 44,300 | 37,157 |
| Greater than one year but less than five years | 17,095 | 1,994 |
| Greater than one year but less than five years | 17,101 | 1,997 |
| Total | 61,357 | 39,156 |
| Total | $ 61,401 | $ 39,154 |
| X | ||||||||||
|
- Definition
This item represents debt securities, at cost, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments, as defined), and fair value hedge accounting adjustments, if any, which are expected to mature after one year and through five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This item represents the fair value of debt securities which are expected to mature after one year and through five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This item represents the total of all debt securities grouped by maturity dates, at cost, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments, as defined), and fair value hedge accounting adjustments, if any, which are classified neither as held-to-maturity nor trading securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This item represents debt securities, at cost, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments, as defined), and fair value hedge accounting adjustments, if any, which are expected to mature within one year of the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This item represents the fair value of debt securities which are expected to mature within one year of the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
For an unclassified balance sheet, total of debt securities categorized neither as held-to-maturity nor trading. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 6 - Foreign Currency Hedging (Detail) (USD $)
|
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Derivative Instruments, Loss Recognized in Other Comprehensive Income (Loss), Effective Portion | $ 1,900,000 | $ 0 | |
| Derivative Instruments, Gain Recognized in Other Comprehensive Income (Loss), Effective Portion | 3,200,000 | ||
| Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net | 18,874 | ||
| Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months | 1,200,000 | ||
|
Sales [Member] | Cash Flow Hedging [Member]
|
|||
| Derivative Instruments, Gain (Loss) Recognized in Income, Net | $ 1,000,000 | $ 5,200,000 | |
| X | ||||||||||
|
- Definition
The amount of net gains and losses recognized in income during the period on derivative instruments designated and qualifying as hedging instruments in fair value hedges and related hedged items designated and qualifying in fair value hedges, on derivative instruments designated and qualifying as hedging instruments in cash flow hedges, and on derivative instruments not designated as hedging instruments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The effective portion of gains on derivative instruments designated and qualifying as hedging instruments that was recognized in other comprehensive income during the current period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The effective portion of losses on derivative instruments designated and qualifying as hedging instruments that was recognized in other comprehensive income during the current period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The net gain (loss) recognized in earnings during the reporting period representing the amount of the cash flow hedges' ineffectiveness. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 6 - Foreign Currency Hedging (Detail) - Schedule of Foreign Currency Exchange Contracts Designated as Cash Flow Hedges (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2011
|
Dec. 31, 2010
|
|---|---|---|
|
Foreign Exchange Forward [Member] | Eurodollar Sell Forward Contract 1.400 [Member]
|
||
| Settlemend Price ($ per Eurodollar) | 1.400 | |
| Notional Amount | $ 25,150 | $ 137,179 |
| Fair Value | 1,837 | 6,740 |
| Notional Amount | 25,150 | 137,179 |
| Fair Value | 1,837 | 6,740 |
|
Foreign Exchange Forward [Member] | Eurodollar Sell Forward Contract 1.200 [Member]
|
||
| Settlemend Price ($ per Eurodollar) | 1.200 | |
| Notional Amount | 117,941 | 117,941 |
| Fair Value | (9,783) | (12,810) |
| Notional Amount | 117,941 | 117,941 |
| Fair Value | (9,783) | (12,810) |
|
Foreign Exchange Forward [Member]
|
||
| Notional Amount | 143,091 | 255,120 |
| Fair Value | (7,946) | (6,070) |
| Notional Amount | 143,091 | 255,120 |
| Fair Value | (7,946) | (6,070) |
|
Foreign Exchange Option [Member] | Eurodollar Purchased Call Option 1.510 [Member]
|
||
| Notional Amount | 27,126 | 147,957 |
| Fair Value | 772 | |
| Strike Price ($ per Eurodollar) | 1.510 | |
| Notional Amount | 27,126 | 147,957 |
| Fair Value | 772 | |
|
Foreign Exchange Option [Member] | Eurodollar Purchased Call Option 1.315 [Member]
|
||
| Notional Amount | 129,244 | 129,244 |
| Fair Value | 5,001 | 10,251 |
| Strike Price ($ per Eurodollar) | 1.315 | |
| Notional Amount | 129,244 | 129,244 |
| Fair Value | 5,001 | 10,251 |
|
Foreign Exchange Option [Member]
|
||
| Notional Amount | 156,370 | 277,201 |
| Fair Value | 5,001 | 11,023 |
| Notional Amount | 156,370 | 277,201 |
| Fair Value | $ 5,001 | $ 11,023 |
| X | ||||||||||
|
- Definition
The strike price on the foreign currency option contract such as a put option or a call option. No definition available.
|
| X | ||||||||||
|
- Definition
The contractual rate at which a foreign currency can be purchased or sold under the terms of a foreign currency derivative contract. No definition available.
|
| X | ||||||||||
|
- Definition
Fair value as of the balance sheet date of all foreign currency derivatives designated as cash flow hedging instruments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate notional amount of all foreign currency derivatives designated as hedging instruments in cash flow hedges. Notional amount refers to the number of currency units specified in the foreign currency derivative contract. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 6 - Foreign Currency Hedging (Detail) - Fair Value of Foreign Currency Exchange Contracts on Condensed Consolidated Balance Sheet (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2011
|
Dec. 31, 2010
|
|---|---|---|
|
Other Assets [Member]
|
||
| Eurodollar contracts, net | $ 1,837 | $ 5,946 |
|
Accrued Liabilities [Member]
|
||
| Foreign currency exchange contracts, net | 4,134 | |
|
Other Liabilities [Member]
|
||
| Foreign currency exchange contracts, net | $ 648 | $ 993 |
| X | ||||||||||
|
- Definition
Fair value as of the balance sheet date of all foreign currency derivative assets designated as cash flow hedging instruments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Fair value as of the balance sheet date of all foreign currency derivative liabilities designated as cash flow hedging instruments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 7 - Prepaid and Other Current Assets (Detail) - Prepaid and Other Current Assets (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2011
|
Dec. 31, 2010
|
|---|---|---|
| Non-recourse Notes issuance costs | $ 1,226 | $ 3,362 |
| Prepaid taxes | 8,297 | 8,307 |
| Other | 654 | 445 |
| Total | 12,014 | 18,060 |
|
Other Assets [Member]
|
||
| Foreign currency exchange | $ 1,837 | $ 5,946 |
| X | ||||||||||
|
- Definition
Carrying amount of current deferred finance costs capitalized at the end of the reporting period related to non-recourse notes. No definition available.
|
| X | ||||||||||
|
- Definition
Fair value as of the balance sheet date of all foreign currency derivative assets designated as cash flow hedging instruments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying amount as of the balance sheet date of payments made in advance for income and other taxes, which will be charged against earnings within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 8 - Property and Equipment (Detail) - Property and Equipment (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2011
|
Dec. 31, 2010
|
|---|---|---|
| Property and equipment, gross | $ 9,139 | $ 9,139 |
| Less accumulated depreciation and amortization | (9,117) | (9,059) |
| Property and equipment, net | 22 | 80 |
|
Leasehold Improvements [Member]
|
||
| Property and equipment, gross | 112 | 112 |
|
Computer and Office Equipment [Member]
|
||
| Property and equipment, gross | 8,989 | 8,989 |
|
Furniture and Fixtures [Member]
|
||
| Property and equipment, gross | $ 38 | $ 38 |
| X | ||||||||||
|
- Definition
The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Gross amount, at the balance sheet date, of long-lived physical assets used in the normal conduct of business and not intended for resale. This can include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 9 - Other Assets (Detail) - Other Assets (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2011
|
Dec. 31, 2010
|
|---|---|---|
| 2012 Notes issuance costs | $ 683 | |
| February 2015 Notes issuance costs | 3,208 | 4,226 |
| May 2015 Notes issuance costs | 4,134 | |
| Non-recourse Notes issuance costs | 2,397 | |
| Other | 12 | |
| Total | $ 7,354 | $ 7,306 |
| X | ||||||||||
|
- Definition
The remaining balance of May 2015 debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective note issues. No definition available.
|
| X | ||||||||||
|
- Definition
The remaining balance of non-recourse debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. No definition available.
|
| X | ||||||||||
|
- Definition
The remaining balance of 2012 debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective note issues. No definition available.
|
| X | ||||||||||
|
- Definition
The remaining balance of 2015 debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective note issues. No definition available.
|
| X | ||||||||||
|
- Definition
Carrying amount as of the balance sheet date of noncurrent assets which have not been itemized or categorized in the footnotes to the financial statements and are a component of Other Assets, Noncurrent (OtherAssetsNoncurrent). Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer). No definition available.
|
| X | ||||||||||
|
- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 10 - Accrued Liabilities (Detail) - Accrued Liabilities (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2011
|
Dec. 31, 2010
|
|---|---|---|
| Compensation | $ 1,341 | $ 349 |
| Interest | 3,351 | 2,794 |
| Deferred revenue | 1,713 | 1,713 |
| Dividend payable | 52 | 20 |
| Other | 1,018 | 2,328 |
| Total | 11,609 | 7,204 |
|
Accrued Liabilities [Member]
|
||
| Foreign currency hedge | $ 4,134 |
| X | ||||||||||
|
- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Fair value as of the balance sheet date of all foreign currency derivative liabilities designated as cash flow hedging instruments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 11 - Commitments and Contingencies (Detail) (USD $)
In Millions, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Operating Leases, Rent Expense | $ 0.2 | $ 0.1 | $ 0.2 |
| X | ||||||||||
|
- Definition
Rental expense incurred for leased assets including furniture and equipment which has not been recognized in costs and expenses applicable to sales and revenues; for example, cost of goods sold or other operating costs and expenses. No definition available.
|
|
Note 11 - Commitments and Contingencies (Detail) - Future Minimum Operating Lease Payments (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2011
|
|---|---|
| 2012 | $ 176 |
| 2013 | 83 |
| Total | $ 259 |
| X | ||||||||||
|
- Definition
The total of future contractually required payments on leases defined as operating. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
For leases having an initial or remaining non-cancelable letter-terms in excess of one year, required rental payments due within the third year of the balance sheet date relating to leases defined as operating. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
For leases having an initial or remaining non-cancelable letter-terms in excess of one year, required rental payments due within the second year of the balance sheet date relating to leases defined as operating. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 12 - Convertible and Non-Recourse Notes (Detail) (USD $)
|
1 Months Ended | 9 Months Ended | 10 Months Ended | 12 Months Ended | 8 Months Ended | 12 Months Ended | 1 Months Ended | 10 Months Ended | 12 Months Ended | 2 Months Ended | 3 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Nov. 30, 2009
|
Sep. 30, 2011
|
Nov. 01, 2010
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
May 17, 2011
|
Dec. 31, 2011
Convertible May 2015 Notes [Member]
|
Dec. 31, 2011
Convertible May 2015 Notes [Member]
|
Dec. 31, 2009
Face Amount [Member]
|
Feb. 28, 2012
Convertible February 2015 Notes [Member]
|
Nov. 01, 2010
Convertible February 2015 Notes [Member]
|
Dec. 31, 2010
Convertible February 2015 Notes [Member]
|
Dec. 31, 2011
Convertible February 2015 Notes [Member]
|
Jan. 05, 2012
Non-Recourse Notes [Member]
|
Dec. 31, 2011
Non-Recourse Notes [Member]
|
Dec. 31, 2010
Non-Recourse Notes [Member]
|
Nov. 30, 2009
Non-Recourse Notes [Member]
|
Feb. 29, 2012
Series 2012 Notes [Member]
|
Jun. 30, 2011
Series 2012 Notes [Member]
|
Jan. 31, 2012
Series 2012 Notes [Member]
|
Jan. 05, 2012
Series 2012 Notes [Member]
|
Dec. 31, 2009
Due 2012 [Member]
Face Amount [Member]
|
Jun. 30, 2011
Due 2012 [Member]
|
Dec. 31, 2010
Due 2012 [Member]
|
Dec. 31, 2009
Due 2012 [Member]
|
Dec. 31, 2010
Due 2023 [Member]
Face Amount [Member]
|
Dec. 31, 2010
Due 2023 [Member]
|
Dec. 31, 2009
Due 2023 [Member]
|
|
| Debt Instrument, Face Amount | $ 155,250,000 | $ 155,250,000 | |||||||||||||||||||||||||||
| Proceeds from Convertible Debt | 149,712,000 | 82,039,000 | 149,700,000 | ||||||||||||||||||||||||||
| Debt Instrument, Convertible, Conversion Ratio | 135.9607 | 155.396 | 155.396 | ||||||||||||||||||||||||||
| Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 7.36 | $ 7.36 | $ 6.44 | $ 6.44 | |||||||||||||||||||||||||
| Debt Instrument, Interest Rate, Stated Percentage | 3.75% | 3.75% | 2.875% | 10.25% | 2.875% | 2.875% | |||||||||||||||||||||||
| Convertible notes repurchase price as a percentage of principal | 100.00% | 100.00% | |||||||||||||||||||||||||||
| Purchased call option and warrants assumed conversion and exercise | During any fiscal quarter ending after the quarter ending June 30, 2011, if the last reported sale price of our common stock for at least 20 trading days in a period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter exceeds 130% of the conversion price for the notes on the last day of such preceding fiscal quarter; During the five business-day period immediately after any five consecutive trading-day period, which we refer to as the measurement period, in which the trading price per $1,000 principal amount of notes for each trading day of that measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate for the notes for each such day; Upon the occurrence of specified corporate events as described further in the indenture; or At any time on or after November 1, 2014. | ||||||||||||||||||||||||||||
| Debt Instrument, Convertible, Effective Interest Rate | 7.50% | ||||||||||||||||||||||||||||
| Debt Instrument, Unamortized Discount | 18,900,000 | 16,298,000 | 16,298,000 | 2,300,000 | |||||||||||||||||||||||||
| Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt | 11,870,000 | 12,300,000 | |||||||||||||||||||||||||||
| Noted obligation allocated to deferred tax liability | 6,600,000 | ||||||||||||||||||||||||||||
| Debt Instrument, Convertible, Remaining Discount Amortization Period | 3.3 | 3.3 | 3.2 | 3 | |||||||||||||||||||||||||
| Number of hedge counterparties | 2 | ||||||||||||||||||||||||||||
| Option Indexed to Issuer's Equity, Shares (in Shares) | 19,600,000 | ||||||||||||||||||||||||||||
| Class of Warrant or Right, Outstanding (in Shares) | 27,500,000 | ||||||||||||||||||||||||||||
| Option Indexed to Issuer's Equity, Strike Price | 7.36 | ||||||||||||||||||||||||||||
| Class of Warrant or Right, Exercise Price of Warrants or Rights | 8.65 | ||||||||||||||||||||||||||||
| Debt Instrument, Convertible, Terms of Conversion Feature | If the share price is above $7.36, upon conversion of our May 2015 Notes, the purchased call options willoffset the share dilution, because the Company will receive shares on exercise of the purchased call options equal to the shares that the Company must deliver to the note holders. If the share price is above $8.65, upon exercise of the warrants, the Company will deliver shares to the counterparties in an amount equal to the excess of the share price over $8.65. For example, a 10% increase in the share price above $8.65 would result in the issuance of 1.9 million incremental shares upon exercise of the warrants. As our share price continues to increase, additional dilution would occur. | ||||||||||||||||||||||||||||
| Purchased call options cost | 20,800,000 | ||||||||||||||||||||||||||||
| Deferred taxes on purchased call options cost | 7,200,000 | ||||||||||||||||||||||||||||
| Number of shares of common stock covered by the purchased call options purchased (in Shares) | 21,100,000 | ||||||||||||||||||||||||||||
| Proceeds from Issuance of Warrants | 10,900,000 | 10,868,000 | |||||||||||||||||||||||||||
| Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 27,500,000 | 27,500,000 | |||||||||||||||||||||||||||
| Debt Conversion, Converted Instrument, Amount | 92,000,000 | 111,680,000 | 10,000,000 | 92,000,000 | 10,000 | 111,700,000 | |||||||||||||||||||||||
| Gains (Losses) on Extinguishment of Debt | 1,100,000 | (766,000) | (17,648,000) | 1,518,000 | 800,000 | 800,000 | 2,400,000 | 700,000 | |||||||||||||||||||||
| Debt Instrument, Increase, Additional Borrowings | 88,000,000 | ||||||||||||||||||||||||||||
| Convertible Debt | 180,000,000 | 169,000,000 | |||||||||||||||||||||||||||
| Unamortized Debt Issuance Expense | 3,200,000 | 1,200,000 | |||||||||||||||||||||||||||
| Debt Instrument, Increase (Decrease) for Period, Net | 133,500,000 | ||||||||||||||||||||||||||||
| Redemption price of face value (in hundredths) | 100.29% | ||||||||||||||||||||||||||||
| Aggregate consideration of redemption | 133,900,000 | ||||||||||||||||||||||||||||
| Debt Instrument, Convertible, Interest Expense | 7,005,000 | 1,000,000 | |||||||||||||||||||||||||||
| Note Face Value Discount Rate Percent | 0.50% | ||||||||||||||||||||||||||||
| Repayments of Convertible Debt | 133,851,000 | 108,247,000 | 69,953,000 | 49,000,000 | 22,000,000 | 2,500,000 | 21,000,000 | 88,400,000 | 104,600,000 | 50,000,000 | |||||||||||||||||||
| Debt Conversion, Converted Instrument, Shares Issued (in Shares) | 1,283 | 20,000,000 | |||||||||||||||||||||||||||
| Notes Payable | $ 409,985,000 | $ 514,698,000 | $ 138,952,000 | $ 138,952,000 | $ 176,964,000 | $ 177,663,000 | $ 93,370,000 | $ 204,270,000 | $ 300,000,000 | $ 133,464,000 | |||||||||||||||||||
| Securitization of Royalties | 60.00% | ||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Total consideration of repayment including principal, interest and applicable premium. No definition available.
|
| X | ||||||||||
|
- Definition
The price at which convertible notes can be repurchased as a percentage of the principal amount plus interest. No definition available.
|
| X | ||||||||||
|
- Definition
The deferred taxes on purchased call options cost. No definition available.
|
| X | ||||||||||
|
- Definition
Adjustment to deferred tax liability resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
Number of counterparties that are part of a contractual agreement. No definition available.
|
| X | ||||||||||
|
- Definition
The number of shares of common stock covered by the purchased call option. No definition available.
|
| X | ||||||||||
|
- Definition
The implications of assumed conversion and exercise of call options and warrants. No definition available.
|
| X | ||||||||||
|
- Definition
Cost of the purchased call options. No definition available.
|
| X | ||||||||||
|
- Definition
Redemption price of face value of notes. No definition available.
|
| X | ||||||||||
|
- Definition
Percent of the net present value of the estimated five year royalties from sales of Genentech products offered in Non-recourse notes. No definition available.
|
| X | ||||||||||
|
- Definition
Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The exercise price of each class of warrants or rights outstanding. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The specified number of securities that each class of warrants or rights outstanding give the holder the right but not the obligation to purchase from the issuer at a specific price, on or before a certain date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate amount of each class of warrants or rights outstanding. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The price per share of the conversion feature embedded in the debt instrument. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The ratio applied to the debt for purposes of determining the number of shares of the equity security into which the debt will be converted. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The effective interest rate on the liability component of convertible debt instrument which may be settled in cash upon conversion, including partial cash settlement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Interest expense related to convertible debt instruments which has been recognized for the period, including the contractual interest coupon and amortization of the debt discount, if any. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Remaining amortization period for any discount on the liability component of convertible debt which may be settled in cash upon conversion. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Description of the conversion terms of a debt instrument which may include the conversion ratio (including all potential conversion ratios if contingently adjustable), type of debt or equity security into which the debt is convertible, the dollars of debt or the number of shares into which the instrument is convertible (or potentially convertible into), the conversion period, any contingencies associated with the conversion terms, and the existence and amount of a beneficial conversion feature. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The stated principal amount of the debt instrument at time of issuance, which may vary from the carrying amount because of unamortized premium or discount. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Increase for additional borrowings on the debt instrument during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Net increase or decrease in the carrying amount of the debt instrument for the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Interest rate stated in the contractual debt agreement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount represents the difference between the fair value of the payments made and the carrying amount of the debt at the time of its extinguishment. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The maximum number of shares that could be issued to net share settle a contract, if applicable. If a contract does not have a fixed or determinable maximum number of shares that may be required to be issued, disclose the fact that a potentially infinite number of shares could be issued to settle the contract. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The exercise (or strike) price stated in the contract. The fixed price at which the option holder can purchase, in the case of a call option, or sell, in the case of a put option, on the underlying security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 12 - Convertible and Non-Recourse Notes (Detail) - Convertible and Non-Recourse Notes (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | 8 Months Ended | 12 Months Ended | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2011
Due 2012 [Member]
|
Dec. 31, 2011
Convertible February 2015 Notes [Member]
|
Dec. 31, 2011
Convertible May 2015 Notes [Member]
|
Dec. 31, 2011
Convertible May 2015 Notes [Member]
|
Dec. 31, 2011
Non-Recourse Notes [Member]
|
Nov. 30, 2009
Non-Recourse Notes [Member]
|
|||||||||
| Balance at December 31, 2010 | $ 514,698 | $ 133,464 | $ 176,964 | $ 204,270 | $ 300,000 | |||||||||||
| Issuance | 136,313 | 136,313 | ||||||||||||||
| Payment | (110,900) | (95,730) | (110,900) | |||||||||||||
| Repurchase | (133,464) | (133,464) | ||||||||||||||
| Discount amortization | 3,338 | 699 | 2,639 | 2,639 | ||||||||||||
| Balance at December 31, 2011 | 409,985 | 514,698 | 177,663 | 138,952 | 138,952 | 93,370 | 300,000 | |||||||||
| Fair value (1) | $ 442,835 | [1] | [1] | $ 191,475 | [1] | $ 156,123 | [1] | $ 156,123 | [1] | $ 95,237 | [1] | |||||
|
||||||||||||||||
| X | ||||||||||
|
- Definition
The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. No definition available.
|
| X | ||||||||||
|
- Definition
The component of interest expense representing the noncash expenses charged against earnings in the period to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate caption: Noncash Interest Expense. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Gross amount of debt extinguished. No definition available.
|
| X | ||||||||||
|
- Definition
Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents notes payable as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 12 - Convertible and Non-Recourse Notes (Detail) - May 2015 Notes (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2011
|
May 17, 2011
|
Dec. 31, 2010
|
|---|---|---|---|
| Unamortized discount of liability component | $ (18,900) | ||
| Net carrying value of the May 2015 Notes | 409,985 | 514,698 | |
|
Convertible May 2015 Notes [Member]
|
|||
| Principal amount of the May 2015 Notes | 155,250 | ||
| Unamortized discount of liability component | (16,298) | ||
| Net carrying value of the May 2015 Notes | $ 138,952 |
| X | ||||||||||
|
- Definition
The stated principal amount of the debt instrument at time of issuance, which may vary from the carrying amount because of unamortized premium or discount. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 12 - Convertible and Non-Recourse Notes (Detail) - Interest Expense for the May 2015 Notes (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | 8 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
Dec. 31, 2011
Convertible May 2015 Notes [Member]
|
Dec. 31, 2011
Convertible May 2015 Notes [Member]
|
|
| Contractual coupon interest | $ 3,639 | ||||
| Amortization of debt issuance costs | 5,386 | 1,682 | 2,159 | 727 | |
| Amortization of debt discount | 3,338 | 2,639 | 2,639 | ||
| Total | $ 7,005 | ||||
| X | ||||||||||
|
- Definition
The component of interest expense representing the noncash expenses charged against earnings in the period to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate caption: Noncash Interest Expense. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The component of interest expense comprised of the periodic charge against earnings over the life of the financing arrangement to which such costs relate. Alternate captions include Noncash Interest Expense. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Interest expense related to convertible debt instruments which has been recognized for the period, including the contractual interest coupon and amortization of the debt discount, if any. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 12 - Convertible and Non-Recourse Notes (Detail) - Future Minimum Principal Payments (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2011
|
|||
|---|---|---|---|---|
| 2012 | $ 93,370 | |||
| 2013 | 0 | |||
| 2014 | 0 | |||
| 2015 | 335,250 | |||
| Total | 428,620 | |||
|
Convertible February 2015 Notes [Member]
|
||||
| 2012 | 0 | |||
| 2013 | 0 | |||
| 2014 | 0 | |||
| 2015 | 180,000 | |||
| Total | 180,000 | |||
|
Convertible May 2015 Notes [Member]
|
||||
| 2012 | 0 | |||
| 2013 | 0 | |||
| 2014 | 0 | |||
| 2015 | 155,250 | |||
| Total | 155,250 | |||
|
Non-Recourse Notes [Member]
|
||||
| 2012 | 93,370 | [1] | ||
| 2013 | 0 | [1] | ||
| 2014 | 0 | [1] | ||
| 2015 | [1] | |||
| Total | $ 93,370 | [1] | ||
|
||||
| X | ||||||||||
|
- Definition
Including current and noncurrent portions, aggregate carrying amount of long-term borrowings as of the balance sheet date. May include notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, which had initial maturities beyond one year or beyond the normal operating cycle, if longer, and after deducting unamortized discount or premiums, if any. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of long-term debt maturing within the next twelve months following the date of the latest balance sheet presented in the financial statements, which may include maturities of long-term debt, sinking fund requirements, and other securities redeemable at fixed or determinable prices and dates. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of long-term debt maturing in year four following the date of the latest balance sheet presented in the financial statements, which may include maturities of long-term debt, sinking fund requirements, and other securities redeemable at fixed of determinable prices and dates. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of long-term debt maturing in year three following the date of the latest balance sheet presented in the financial statements, which may include maturities of long-term debt, sinking fund requirements, and other securities redeemable at fixed of determinable prices and dates. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of long-term debt maturing in year two following the date of the latest balance sheet presented in the financial statements, which may include maturities of long-term debt, sinking fund requirements, and other securities redeemable at fixed or determinable prices and dates. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 13 - Other Long-Term Liabilities (Detail)
|
Dec. 31, 2011
USD ($)
|
Dec. 31, 2010
USD ($)
|
Dec. 31, 2010
AFN
|
|---|---|---|---|
| Guarantor Obligations, Maximum Exposure, Undiscounted | $ 110,800,000 | ||
| Accrued Rent, Noncurrent | $ 10,700,000 | $ 10,700,000 | 10,700,000 |
| X | ||||||||||
|
- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer) for contractual rent under lease arrangements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 13 - Other Long-Term Liabilities (Detail) - Other Long-Term Liabilities
In Thousands, unless otherwise specified |
Dec. 31, 2011
USD ($)
|
Dec. 31, 2010
USD ($)
|
Dec. 31, 2010
AFN
|
Dec. 31, 2011
Other Liabilities [Member]
USD ($)
|
Dec. 31, 2010
Other Liabilities [Member]
USD ($)
|
|---|---|---|---|---|---|
| Accrued lease liability | $ 10,700 | $ 10,700 | 10,700 | ||
| Accrued legal settlement | 27,500 | ||||
| Uncertain tax position | 12,774 | 12,213 | |||
| Foreign currency hedge | 648 | 993 | |||
| Total | $ 24,122 | $ 51,406 |
| X | ||||||||||
|
- Definition
Legal settlement expense to be paid in one year or more of the date of the statement of financial position. No definition available.
|
| X | ||||||||||
|
- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer) for contractual rent under lease arrangements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Fair value as of the balance sheet date of all foreign currency derivative liabilities designated as cash flow hedging instruments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The noncurrent portion of the amount recognized for uncertain tax positions as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 14 - Stock-Based Compensation (Detail) (USD $)
|
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in Shares) | 136,507 | 40,000 | 148,000 |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | $ 45,000 | ||
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term | 2.33 | ||
| Closing Market Price of Company's Stock (in Dollars per share) | $ 6.20 | ||
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period (in Shares) | 43,000 | 1,290,000 | 3,999,000 |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price (in Dollars per share) | $ 20.67 | $ 20.36 | $ 17.96 |
|
Directors and Employees [Member]
|
|||
| Allocated Share-based Compensation Expense, Net of Tax | 337,000 | 662,000 | 773,000 |
|
Restricted Stock [Member]
|
|||
| Allocated Share-based Compensation Expense, Net of Tax | 400,000 | 600,000 | 500,000 |
| Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period, Minimum | twelve | ||
| Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period, Maximum | twenty-four | ||
| Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Intrinsic Value (in Dollars per share) | $ 800,000 | ||
| Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized | 500,000 | ||
| Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition | 10 | ||
|
Non-Employees [Member]
|
|||
| Allocated Share-based Compensation Expense, Net of Tax | $ 50,000 | $ 0 | $ 48,000 |
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
The amount of expense, net of income tax, recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees. No definition available.
|
| X | ||||||||||
|
- Definition
As of the balance sheet date, the aggregate unrecognized cost of equity-based awards made to employees under equity-based compensation awards that have yet to vest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, using a decimal to express in number of years. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The maximum vesting term over which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition. No definition available.
|
| X | ||||||||||
|
- Definition
The minimum vesting term over which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition. No definition available.
|
| X | ||||||||||
|
- Definition
The intrinsic value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units, as calculated by applying the disclosed pricing methodology. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The total dollar difference between fair values of the underlying shares reserved for issuance and exercise prices of vested portions of options outstanding and currently exercisable under the option plan as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted average period between the balance sheet date and expiration for all vested portions of options outstanding and currently exercisable (or convertible) under the plan, which may be expressed in a decimal value for number of years. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated during the reporting period due to noncompliance with plan terms during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 14 - Stock-Based Compensation (Detail) - Shares of Company Common Stock Available Under Share-Based Plans
|
12 Months Ended | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
Dec. 31, 2008
|
Dec. 31, 2011
2005 Equity Incentive Plan [Member]
|
Dec. 31, 2011
2002 Outside Directors Stock Option Plan [Member]
|
Dec. 31, 2011
1999 Non-statutory Stock Option Plan [Member]
|
Dec. 31, 2011
1999 Stock Option Plan [Member]
|
|||||||||
| Shares of Common Stock Authorized Under Plan | 5,200,000 | [1] | 157,000 | [2] | 5,075,707 | [2] | 3,758,719 | [2] | ||||||||
| Total Shares of Common Stock Issued Under Plan | 490,143 | [1] | 140,750 | [2] | 4,966,183 | [2] | 3,653,150 | [2] | ||||||||
| Total Shares of Common Stock Subject to Outstanding Awards Under Plan | 231,000 | 274,000 | 1,564,000 | 5,776,000 | 0 | [1] | 16,250 | [2] | 109,524 | [2] | 105,569 | [2] | ||||
| Total Shares of Common Stock Available for Grant Under Plan | 4,709,857 | [1] | [2] | [2] | [2] | |||||||||||
|
||||||||||||||||
| X | ||||||||||
|
- Definition
The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of shares newly issued during the reporting period under the plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 14 - Stock-Based Compensation (Detail) - Stock Option Activity (USD $)
In Thousands, except Per Share data, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Outstanding at beginning of year | 274 | 1,564 | 5,776 |
| Outstanding at beginning of year (in Dollars per share) | $ 17.25 | $ 19.82 | $ 18.04 |
| Exercised | 0 | 0 | (213) |
| Exercised (in Dollars per share) | $ 0 | $ 0 | $ 6.57 |
| Forfeited | (43) | (1,290) | (3,999) |
| Forfeited (in Dollars per share) | $ 20.67 | $ 20.36 | $ 17.96 |
| Outstanding at end of year | 231 | 274 | 1,564 |
| Outstanding at end of year (in Dollars per share) | $ 16.62 | $ 17.25 | $ 19.82 |
| Exercisable at end of year | 231 | 274 | 1,543 |
| Exercisable at end of year (in Dollars per share) | $ 16.62 | $ 17.25 | $ 20.01 |
| X | ||||||||||
|
- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted average price at which option holders acquired shares when converting their stock options into shares under the plan during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated during the reporting period due to noncompliance with plan terms during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted average price as of the beginning of the year at which grantees can acquire the shares reserved for issuance under the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of share options (or share units) exercised during the current period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 14 - Stock-Based Compensation (Detail) - Additional Information Regarding Our Options Exercised (USD $)
In Thousands, unless otherwise specified |
12 Months Ended |
|---|---|
|
Dec. 31, 2009
|
|
| Cash received | $ 1,402 |
| Aggregate intrinsic value | $ 326 |
| X | ||||||||||
|
- Definition
The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The total accumulated difference between fair values of underlying shares on dates of exercise and exercise price on options which were exercised (or share units converted) into shares during the reporting period under the plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 14 - Stock-Based Compensation (Detail) - Restricted Stock Activity (USD $)
|
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Nonvested at beginning of year | 40,000 | 148,000 | |
| Nonvested at beginning of year (in Dollars per share) | $ 5.05 | $ 6.54 | |
| Nonvested at end of year | 136,507 | 40,000 | 148,000 |
| Nonvested at end of year (in Dollars per share) | $ 6.09 | $ 5.05 | $ 6.54 |
| Awards granted | 155,000 | 40,000 | 159,000 |
| Awards granted (in Dollars per share) | $ 6.15 | $ 5.05 | $ 6.54 |
| Awards vested | (40,000) | (148,000) | (5,000) |
| Awards vested (in Dollars per share) | $ 5.05 | $ 6.54 | $ 6.43 |
| Forfeited | (18,000) | 0 | (6,000) |
| Forfeited (in Dollars per share) | $ 6.59 | $ 0 | $ 6.66 |
| X | ||||||||||
|
- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect during the reporting period as a result of the occurrence of a terminating event specified in the contractual agreement of the plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 15 - Cash Dividends (Detail) (USD $)
|
12 Months Ended | 0 Months Ended | 12 Months Ended | |||||
|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2012
|
Jan. 18, 2012
|
Feb. 25, 2011
|
Oct. 02, 2010
Special Cash Dividends Declared [Member]
|
Apr. 02, 2011
Special Cash Dividends Declared [Member]
|
Jan. 31, 2010
Special Cash Dividends Declared [Member]
|
Dec. 31, 2010
Restricted Stock [Member]
|
|
| Dividends Payable, Amount Per Share (in Dollars per share) | $ 0.15 | $ 0.15 | $ 0.50 | |||||
| Dividends Payable Dates To be Paid Day Month And Year | March14, June14,September14 and December14 of 2012 | March15, June15,September15 and December15 of 2011 | ||||||
| Dividends Payable Dates of Record, Day, Month and Year | March7, June7,September7 and December 7 of 2012 | March8, June8,September8 and December8 of 2011 | ||||||
| Dividends, Cash (in Dollars) | $ 83,800,000 | $ 69,800,000 | $ 59,900,000 | |||||
| Dividends Payable, Amount (in Dollars) | $ 20,000 |
| X | ||||||||||
|
- Definition
Declaration of date(s) as of when a holder must own the stock to be entitled to the dividend. The ex-dividend date is generally 3 days before the record date. No definition available.
|
| X | ||||||||||
|
- Definition
For declared dividends, day, month, and year (YYYY-MM-DD) that the dividend declared as of or prior to the financial reporting date will be paid in the subsequent period. No definition available.
|
| X | ||||||||||
|
- Definition
Equity impact of cash dividends declared by an entity during the period for all classes of stock (common, preferred, etc.). This element includes paid and unpaid dividends declared during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate amount of dividends declared, but not paid, as of the financial reporting date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The per share amount of a dividend declared, but not paid, as of the financial reporting date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 16 - Customer Concentration (Detail)
|
Dec. 31, 2011
|
|---|---|
| Minimum threshold percent of total royalty income requiring disclosure by licensee by product name (in hundredths) | 10.00% |
| X | ||||||||||
|
- Definition
Minimum threshold percent of total royalty income requiring disclosure by licensee by product name. No definition available.
|
|
Note 16 - Customer Concentration (Detail) - Percentage of Total Revenue From Licenses Over 10% of Revenue
|
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
|
Genentech [Member]
|
|||
| Licensees | |||
| Minimum threshold percent of total royalty income requiring disclosure by license by product name - year to date (in hundredths) | 86.00% | 86.00% | 71.00% |
|
Elan [Member]
|
|||
| Licensees | |||
| Minimum threshold percent of total royalty income requiring disclosure by license by product name - year to date (in hundredths) | 12.00% | 10.00% | 9.00% |
|
MedImmune [Member]
|
|||
| Licensees | |||
| Minimum threshold percent of total royalty income requiring disclosure by license by product name - year to date (in hundredths) | 0.00% | 0.00% | 13.00% |
| X | ||||||||||
|
- Definition
Percentage of revenue generated from a single external customer that accounts for 10 percent or more of an entity's revenues. No definition available.
|
| X | ||||||||||
|
- Details
|
|
Note 16 - Customer Concentration (Detail) - Total Revenues by Geographic Area (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| United States | $ 137,269 | $ 130,070 | $ 154,706 |
| Total revenues | 362,041 | 344,975 | 318,184 |
|
Europe [Member]
|
|||
| Foreign Revenues | 224,472 | 213,677 | 160,743 |
|
Other Geographic Areas [Member]
|
|||
| Foreign Revenues | $ 300 | $ 1,228 | $ 2,735 |
| X | ||||||||||
|
- Definition
Revenues from external customers attributed to the entity's country of domicile. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Revenues from external customers attributed to all foreign countries in total from which the entity derives revenues. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 17 - Income Taxes (Detail) (USD $)
|
12 Months Ended | 132 Months Ended | |||
|---|---|---|---|---|---|
|
Dec. 31, 2023
|
Dec. 31, 2011
|
Dec. 31, 2022
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Operating Loss Carryforwards | $ 42,900,000 | $ 44,700,000 | |||
| Operating Loss Carryforwards, Expiration Dates | 2023 | ||||
| Operating Loss Carryforwards, Limitations on Use | $1.3 for the year ended December31, 2023 | We have an annual limitation on the use of our federal operating losses of $1.8 million for each of the years ended December31, 2012 to 2022 | |||
| Operating Loss Carryforwards, Valuation Allowance | 22,000,000 | ||||
| Unrecognized Tax Benefits | 23,061,000 | 23,061,000 | 23,116,000 | ||
| Unrecognized Tax Benefits that Would Impact Effective Tax Rate | 12,200,000 | ||||
| Unrecognized Tax Benefits Resulting in Adjustment to Deferred Tax Assets | 10,900,000 | ||||
| Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued | $ 500,000 | $ 26,000 | $ 400,000 | ||
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
The sum of domestic, foreign and state and local operating loss carryforwards, before tax effects, available to reduce future taxable income under enacted tax laws. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The expiration date of each operating loss carryforward included in total operating loss carryforwards, or the applicable range of such expiration dates. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income. No definition available.
|
| X | ||||||||||
|
- Definition
The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The gross amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This element represents the total of accruals as of the date of the statement of financial position for interest recognized for an underpayment of income taxes computed by applying the applicable statutory rate of interest to the difference between a tax position recognized for financial reporting purposes and the amount previously taken or expected to be taken in a tax return of the entity and the amount of statutory penalties for a tax position claimed or expected to be claimed by the entity, in its tax return, that does not meet the minimum statutory threshold to avoid payment of penalties. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 17 - Income Taxes (Detail) - Provision for Income Taxes (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Current income tax expense | |||
| Federal | $ 83,569 | $ 91,325 | $ 87,402 |
| State | 1 | 11 | (573) |
| Total current | 83,570 | 91,336 | 86,829 |
| Deferred income tax (benefit) | 24,469 | (32,840) | 3,796 |
| Total provision | $ 108,039 | $ 58,496 | $ 90,625 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The component of income tax expense for the period representing amounts paid or payable (or refundable) as determined by applying the provisions of enacted federal tax law to the domestic taxable Income or Loss from continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The component of income tax expense for the period representing amounts of income taxes paid or payable (or refundable) for the period for all income tax obligations as determined by applying the provisions of relevant enacted tax laws to relevant amounts of taxable Income or Loss from continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The component of income tax expense for the period representing amounts paid or payable (or refundable) as determined by applying the provisions of enacted state and local tax law to relevant amounts of taxable Income or Loss from continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The component of total income tax expense for the period comprised of the increase (decrease) during the period in the entity's domestic deferred tax assets and liabilities attributable to continuing operations as determined by applying the provisions of the federally enacted tax law. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 17 - Income Taxes (Detail) - Reconciliation of the Income Tax Provision Computed Using the U.S. Statutory Federal Income Tax Rate (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Tax at U.S. statutory rate on income before income taxes | $ 107,600 | $ 52,630 | $ 98,100 |
| Change in valuation allowance | 296 | 4,891 | |
| State taxes | 1 | 11 | (573) |
| Net operating loss re-establishment | (9,174) | ||
| Non-deductible loss on retirement or conversion of convertible notes | 4,960 | ||
| Other | 438 | 599 | (2,619) |
| Total | $ 108,039 | $ 58,496 | $ 90,625 |
| X | ||||||||||
|
- Definition
The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to pretax Income or Loss from continuing operations; income tax expense or benefit may include interest and penalties on tax uncertainties based on the entity's accounting policy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of the difference between total income tax expense or benefit as reported in the Income Statement and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to changes in the valuation allowance for deferred tax assets in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to other deductions received under enacted tax laws not otherwise listed in the existing taxonomy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to nondeductible expenses under enacted tax laws, or differences in the methodologies used to determine expense amounts for financial statements prepared in accordance with generally accepted accounting principles, not otherwise listed in the existing taxonomy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of the difference, between total income tax expense or benefit as reported in the Income Statement for the year/accounting period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations, that is attributable to all other items not otherwise listed in the existing taxonomy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of the difference, between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations, that is attributable to state and local income tax expense or benefit. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 17 - Income Taxes (Detail) - Deferred Tax Assets and Liabilities (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2011
|
Dec. 31, 2010
|
|---|---|---|
| Deferred tax assets: | ||
| Net operating loss carryforwards | $ 7,308 | $ 7,930 |
| Research and other tax credits | 5,743 | 5,743 |
| Intangible assets | 7,403 | 8,952 |
| Stock-based compensation | 273 | 339 |
| Reserves and accruals | 10,087 | 32,541 |
| Deferred revenue | 600 | 599 |
| Unrealized loss on foreign currency hedge contracts | 1,031 | |
| Other | 974 | 506 |
| Total deferred tax assets | 33,419 | 56,610 |
| Valuation allowance | (10,930) | (10,930) |
| Total deferred tax assets, net of valuation allowances | 22,489 | 45,680 |
| Deferred tax liabilities: | ||
| Deferred gain on repurchase of convertible notes | (954) | (1,079) |
| Unrealized gain on foreign currency hedge contracts | (2,079) | |
| Total deferred tax liabilities | (954) | (3,158) |
| Net deferred tax assets | $ 21,535 | $ 42,522 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The cumulative amount for all deferred tax liabilities as of the balance sheet date arising from temporary differences between accounting income in accordance with generally accepted accounting principles and tax-basis income that will result in future taxable income exceeding future accounting income. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The tax effect as of the balance sheet date of the amount of the estimated future tax deductions attributable to income recognized only for tax purposes and which will reverse when recognized under generally accepted accounting principles. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The sum of the tax effects as of the balance sheet date of the amounts of all future tax deductions arising from temporary differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws ( before the valuation allowance, if any, to reduce such sum amount to net realizable value). Includes any tax benefit realized in deferred tax assets for significant impacts of tax planning strategies. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
For entities that net deferred tax assets and tax liabilities, represents the unclassified net amount of deferred tax assets and liabilities as of the balance sheet date, which result from applying the applicable enacted tax rate to net temporary differences and carryforwards pertaining to assets or liabilities. A temporary difference is a difference between the tax basis of an asset or liability and its carrying amount in the financial statements prepared in accordance with generally accepted accounting principles that will reverse in ensuing periods. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate tax effects as of the balance sheet date of all future tax deductions arising from temporary differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws; net of deducting the allocated valuation allowance, if any, to reduce such amount to net realizable value. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The tax effect as of the balance sheet date of the amount of excess of tax deductions over gross income in a year which cannot be used on the tax return of the country of domicile in the current year but can be carried forward to reduce taxable income or income taxes payable in a future year, for which there must be sufficient tax-basis income to utilize a portion or all of the carryforward amount to realize the deferred tax asset. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The tax effect as of the balance sheet date of the amount of estimated future tax deductions arising from other temporary differences not otherwise specified in the taxonomy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The tax effect as of the balance sheet date of the amount of future tax deductions arising from unused research tax credit carryforwards; a tax credit carryforward is the amount by which tax credits available for utilization exceed statutory limitations for inclusion in historical filings, and which can only be utilized if sufficient tax-basis income is generated in future periods and providing tax laws continue to allow such utilization. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from equity-based compensation costs, which can only be deducted for tax purposes when actual costs are incurred, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The tax effect as of the balance sheet date of the amount of the estimated future tax effects arising from all other reserves, which can only be deducted for tax purposes when losses pertaining to such reserves are actually incurred, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from unrealized losses on foreign currency transactions which can only be deducted for tax purposes when the losses are realized, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The sum of the portions of deferred tax assets as of the balance sheet date for which, based on the weight of available evidence, it is more likely than not will not be realized through future reductions of tax-based income. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The amount as of the balance sheet date of the estimated future tax effects attributable to differences between the methods used to account for financing arrangements for tax purposes and under generally accepted accounting principles which will increase future taxable income when such differences reverse. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cumulative amount of the estimated future tax effects attributable to the difference between the tax basis of intangible assets and the basis of intangible assets computed in accordance with generally accepted accounting principles. The difference in basis, whether due to amortization or other reasons, will increase future taxable income when such difference reverses. Intangible assets include, but are not limited to, assets such as patents, trademarks and customer lists. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount as of the balance sheet date of the estimated future tax effects arising from unrealized gains on foreign currency transactions that were recognized as income in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 17 - Income Taxes (Detail) - Unrecognized Tax Benefits (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | |
|---|---|---|
|
Dec. 31, 2010
|
Dec. 31, 2011
|
|
| Balance at the beginning of the year | $ 23,116 | $ 23,061 |
| Balance at the end of the year | 23,061 | 23,061 |
| Expiration of statute of limitations for the assessment of taxes | $ (55) |
| X | ||||||||||
|
- Definition
The gross amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The gross amount of decreases in unrecognized tax benefits resulting from lapses of the applicable statutes of limitations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 18 - Legal Proceedings (Detail) (USD $)
|
12 Months Ended | 1 Months Ended | 13 Months Ended | 1 Months Ended | |||
|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
Jul. 07, 2011
|
Dec. 31, 2011
Europe [Member]
|
Feb. 09, 2012
MedImmune [Member]
|
Feb. 15, 2011
MedImmune [Member]
|
Feb. 09, 2012
MedImmune [Member]
|
Feb. 02, 2011
UCB Pharma S.A. [Member]
|
|
| Payments for Legal Settlements | $ 27,500,000 | $ 65,000,000 | $ 92,500,000 | ||||
| Proceeds from Legal Settlements | 10,000,000 | ||||||
| RoyaltyRevenueGeographicConcentration | 33.00% | ||||||
| Gain Contingency, Unrecorded Amount | $ 1,000,000,000 | ||||||
| Royalty Rate | 3.75% | ||||||
| Number of Genentech's Claims Dismissed by Court | 2 | ||||||
| Number of PDL's Claims Upheld by Court | 4 | ||||||
| Number of PDL's claims for relief relating to the 2003 settlement agreement | 5 | ||||||
| Number of PDL's claims dismissed by the court | 1 | ||||||
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
Number of PDL's claims dismissed by the court No definition available.
|
| X | ||||||||||
|
- Definition
Number of PDL's claims for relief relating to the 2003 settlement agreement. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
Retroactive royalty rate on past US-based Sales of the Genentech Products and interest, among other items. No definition available.
|
| X | ||||||||||
|
- Definition
Revenues derived from sales of products that were made in US and foreign geographies. No definition available.
|
| X | ||||||||||
|
- Definition
The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of cash paid for the settlement of litigation or for other legal issues during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Cash received for the settlement of litigation during the current period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 19 - Subsequent Event (Detail) (USD $)
Share data in Thousands, except Per Share data, unless otherwise specified |
2 Months Ended | 10 Months Ended | 12 Months Ended | 1 Months Ended | 10 Months Ended | 12 Months Ended | 2 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Feb. 29, 2012
|
Nov. 01, 2010
|
Dec. 31, 2010
|
Feb. 28, 2012
Convertible February 2015 Notes [Member]
|
Jan. 31, 2012
Convertible February 2015 Notes [Member]
|
Nov. 01, 2010
Convertible February 2015 Notes [Member]
|
Dec. 31, 2010
Convertible February 2015 Notes [Member]
|
Feb. 02, 2012
Convertible February 2015 Notes [Member]
|
Jan. 05, 2012
Convertible February 2015 Notes [Member]
|
Feb. 29, 2012
Series 2012 Notes [Member]
|
Feb. 02, 2012
Series 2012 Notes [Member]
|
Jan. 31, 2012
Series 2012 Notes [Member]
|
Jan. 05, 2012
Series 2012 Notes [Member]
|
|
| Percentage of Convertible Notes Exchanged | 93.90% | ||||||||||||
| Debt Instrument, Interest Rate, Stated Percentage | 2.875% | 2.875% | |||||||||||
| Convertible Debt | $ 180,000,000 | $ 169,000,000 | |||||||||||
| Incentive Fee Per Thousand to Convert Debt | 5.00 | ||||||||||||
| Induced Conversion of Convertible Debt Expense | 800,000 | ||||||||||||
| Debt Conversion, Converted Instrument, Amount | 92,000,000 | 111,680,000 | 10,000,000 | 92,000,000 | |||||||||
| Convertible Notes Payable | $ 1,000,000 | $ 179,000,000 | |||||||||||
| Incremental Common Shares Attributable to Conversion of Debt Securities (in Shares) | 27,800 | ||||||||||||
| Debt Instrument, Convertible, Conversion Ratio | 155.3960 | 155.3960 | |||||||||||
| Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 6.44 | $ 6.44 | |||||||||||
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The price per share of the conversion feature embedded in the debt instrument. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The ratio applied to the debt for purposes of determining the number of shares of the equity security into which the debt will be converted. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Interest rate stated in the contractual debt agreement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 20 - Quarterly Financial Data (Unaudited) (Detail) - Quarterly Financial Data (Unaudited) (USD $)
In Thousands, except Per Share data, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Revenues | $ 362,041 | $ 344,975 | $ 318,184 |
| Net income | 199,389 | 91,874 | 189,660 |
| Net income per basic share (in Dollars per share) | $ 1.43 | $ 0.73 | $ 1.59 |
| Net income per diluted share (in Dollars per share) | $ 1.15 | $ 0.54 | $ 1.07 |
|
Quarter Ending December 31 [Member]
|
|||
| Revenues | 72,808 | 76,129 | |
| Net income | 38,942 | (24,460) | |
| Net income per basic share (in Dollars per share) | $ 0.28 | $ (0.18) | |
| Net income per diluted share (in Dollars per share) | $ 0.24 | $ (0.18) | |
|
Quarter Ending September 30 [Member]
|
|||
| Revenues | 83,770 | 86,442 | |
| Net income | 45,916 | 40,189 | |
| Net income per basic share (in Dollars per share) | $ 0.33 | $ 0.32 | |
| Net income per diluted share (in Dollars per share) | $ 0.28 | $ 0.24 | |
|
Quarter Ending June 30 [Member]
|
|||
| Revenues | 122,127 | 120,343 | |
| Net income | 69,986 | 50,138 | |
| Net income per basic share (in Dollars per share) | $ 0.50 | $ 0.42 | |
| Net income per diluted share (in Dollars per share) | $ 0.38 | $ 0.30 | |
|
Quarter Ending March 31 [Member]
|
|||
| Revenues | 83,336 | 62,061 | |
| Net income | $ 44,545 | $ 26,007 | |
| Net income per basic share (in Dollars per share) | $ 0.32 | $ 0.22 | |
| Net income per diluted share (in Dollars per share) | $ 0.25 | $ 0.15 | |
| X | ||||||||||
|
- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|